JNeurosci
THE JOURNAL OF NEUROSCIENCE

Research Articles: Development/Plasticity/Repair

Conditional BDNF delivery from astrocytes rescues memory deficits, spine density and synaptic properties in the 5xFAD mouse model of Alzheimer disease

Benoit de Pins[1,2,3], Carmen Cifuentes-Díaz[1,2,3], Amel Thamila Farah[1,2,3], Laura López-Molina[4,5,6], Enrica Montalban[1,2,3], Anna Sancho-Balsells[4,5,6], Ana López[4,5,6], Silvia Ginés[4,5,6], José María Delgado-García[7], Jordi Alberch[4,5,6], Agnès Gruart[7], Jean-Antoine Girault[1,2,3] and Albert Giralt[4,5,6]

[1]*Inserm UMR-S 839, Paris, France.*

[2]*Sorbonne Université, Faculty of Sciences and Engineering, Paris, France.*

[3]*Institut du Fer à Moulin, Paris 75005, France.*

[4]*Departament de Biomedicina, Facultat de Medicina, Institut de Neurociències, Universitat de Barcelona, Barcelona, 08036 Spain.*

[5]*Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona 08036, Spain.*

[6]*Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid 28031, Spain.*

[7]*Division of Neurosciences, Pablo de Olavide University, Seville 41013, Spain*

https://doi.org/10.1523/JNEUROSCI.2121-18.2019

Received: 17 August 2018

Revised: 23 January 2019

Accepted: 25 January 2019

Published: 30 January 2019

Author contributions: B.d.P., C.C.-D., A.T.F., L.L.-M., E.M., A.S.-B., A.L., A. Gruart, and A. Giralt performed research; B.d.P., C.C.-D., J.M.D.-G., A. Gruart, and A. Giralt analyzed data; S.G., J.M.D.-G., J.A., A. Gruart, J.-A.G., and A. Giralt designed research; J.M.D.-G., J.A., A. Gruart, J.-A.G., and A. Giralt wrote the paper; A. Gruart and A. Giralt edited the paper.

Conflict of Interest: The authors declare no competing financial interests.

Authors want to thank Ms. María Sánchez Enciso and Mr. José M. González Martín for their help in animal handling and care during ***in vivo*** experiments. AGi is a Ramón y Cajal fellow (RYC-2016-19466). JAG lab was supported in part by Inserm, ***Sorbonne*** Université, the ***Fondation pour la Recherche Médicale***, and the Bio-Psy (Biology for Psychiatry) laboratory of excellence. The cell and tissue imaging facility at the IFM benefited from supports of ***Espoir en Tête/Fondation pour la Recherche sur le Cerveau,Région Ile-de-France***, and Inserm. AGr and JMDG research was supported by grants BFU2017-82375-R from MINECO and from the Tatiana Pérez de Guzman el Bueno Foundation. JA research was supported by grants SAF2017-88076 and Marató TV3 Foundation. SG research was supported by grant SAF2015-67474-R.

Correspondence to: Albert Giralt, Departament de Biomedicina, Facultat de Medicina, Institut de Neurociències, Universitat de Barcelona, Barcelona 08036, Spain. E-mail: albertgiralt@ub.edu

Cite as: J. Neurosci 2019; 10.1523/JNEUROSCI.2121-18.2019

Conditional BDNF delivery from astrocytes rescues memory deficits, spine density and synaptic properties in the 5xFAD mouse model of Alzheimer disease

Abbreviated title: BDNF conditional delivery from astrocytes in AD

Benoit de Pins[1,2,3], Carmen Cifuentes-Díaz[1,2,3], Amel Thamila Farah[1,2,3], Laura López-Molina,[4,5,6] Enrica Montalban[1,2,3], Anna Sancho-Balsells,[4,5,6] Ana López[4,5,6], Silvia Ginés[4,5,6], José María Delgado-García[7], Jordi Alberch[4,5,6], Agnès Gruart[7], Jean-Antoine Girault[1,2,3] and Albert Giralt[4,5,6,*]

[1]Inserm UMR-S 839, Paris, France. [2] Sorbonne Université, Faculty of Sciences and Engineering, Paris, France. [3]Institut du Fer à Moulin, Paris 75005, France. [4]Departament de Biomedicina, Facultat de Medicina, Institut de Neurociències, Universitat de Barcelona, Barcelona, 08036 Spain. [5]Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona 08036, Spain. [6]Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid 28031, Spain. [7]Division of Neurosciences, Pablo de Olavide University, Seville 41013, Spain

* Correspondence to: **Albert Giralt**, Departament de Biomedicina, Facultat de Medicina, Institut de Neurociències, Universitat de Barcelona, Barcelona 08036, Spain. E-mail: albertgiralt@ub.edu

The authors declare no competing financial interests

Number of pages: 49
Number of figures: 7
Number of words in the abstract section: 245
Number of words in the significance statement: 125
Number of words in the introduction section: 647
Number of words in the discussion section: 1,646

Acknowledgements

Authors want to thank Ms. María Sánchez Enciso and Mr. José M. González Martín for their help in animal handling and care during *in vivo* experiments. AGi is a Ramón y Cajal fellow (RYC-2016-19466). JAG lab was supported in part by Inserm, *Sorbonne* Université, the *Fondation pour la Recherche Médicale*, and the Bio-Psy (Biology for Psychiatry) laboratory of excellence. The cell and tissue imaging facility at the IFM benefited from supports of *Espoir en Tête/Fondation pour la Recherche sur le Cerveau, Région Ile-de-France*, and Inserm. AGr and JMDG research was supported by grants BFU2017-82375-R from MINECO and from the Tatiana Pérez de Guzman el Bueno Foundation. JA research was supported by grants SAF2017-88076 and Marató TV3 Foundation. SG research was supported by grant SAF2015-67474-R.

Abstract

It has been well documented that neurotrophins, including brain-derived neurotrophic factor (BDNF), are severely affected in Alzheimer's disease (AD) but their administration faces a myriad of technical challenges. Here we took advantage of the early astrogliosis observed in an amyloid mouse model of AD (5xFAD) and used it as an internal sensor to administer BDNF conditionally and locally. We first demonstrate the relevance of BDNF release from astrocytes by evaluating the effects of co-culturing wild type neurons and BDNF-deficient astrocytes. Next, we crossed 5xFAD mice with pGFAP:BDNF mice (only males were used) to create 5xFAD mice that over-express BDNF when and where astrogliosis is initiated (5xF:pGB mice). We evaluated the behavioral phenotype of these mice. We first found that BDNF from astrocytes is crucial for dendrite outgrowth and spine number in cultured wild type neurons. Double mutant 5xF:pGB mice displayed improvements in cognitive tasks as compared to 5xFAD littermates. In these mice, there was a rescue of BDNF/TrkB downstream signaling activity associated with an improvement of dendritic spine density and morphology. Clusters of synaptic markers, PSD-95 and synaptophysin, were also recovered in 5xF:pGB as compared to 5xFAD mice as well as the number of pre-synaptic vesicles at excitatory synapses. Additionally, experimentally-evoked LTP *in vivo* was increased in 5xF:pGB mice. The beneficial effects of conditional BDNF production and local delivery at the location of active neuropathology highlight the potential to use endogenous biomarkers with early onset such as astrogliosis as regulators of neurotrophic therapy in AD.

Key words: Long-term potentiation, synaptophysin, PSD-95, 5xFAD, hippocampus, memory.

Significance statement

Recent evidence places astrocytes as pivotal players during synaptic plasticity and memory processes. In the present work we first provide evidence that astrocytes are essential for neuronal morphology via BDNF release. We then crossed transgenic mice (5xFAD mice) with the transgenic pGFAP-BDNF mice which express BDNF under the glial fibrillary astrocytic protein (GFAP) promoter. The resultant double mutant mice 5xF:pGB mice displayed a full rescue of hippocampal BDNF loss and related signaling compared with 5xFAD mice and a significant and specific improvement in all the evaluated cognitive tasks. These improvements did not correlate with amelioration of beta amyloid load or hippocampal adult neurogenesis rate but were accompanied by a dramatic recovery of structural and functional synaptic plasticity.

Introduction

Alzheimer disease (AD) is the most common form of dementia in the aging population accounting for 60–80% of the cases. The disease is a progressive neurodegenerative disorder characterized by the presence of extracellular amyloid plaques composed of amyloid-β (Aβ) surrounded by dystrophic neurites and neurofibrillary tangles (NFTs) (Alzheimer's Association, 2012). Further pathological hallmarks of the disease include inflammatory processes, synaptic and neuronal loss, cerebral atrophy, and cerebral amyloid angiopathy (Wirths and Bayer, 2012). The complex progression of neurodegeneration in AD patients results in memory impairment and decline in other cognitive abilities often combined with non-cognitive symptoms like mood- and personality changes (Alzheimer's Association, 2012).

One of the most promising therapies in AD is the use of neurotrophic factors such as nerve growth factor (NGF) or brain-derived neurotrophic factor (BDNF) (Allen and Dawbarn, 2006). Indeed, BDNF plays important roles in neural survival and synaptic plasticity (Lynch et al., 2008). In line with this, BDNF is reduced early in the course of the disease in transgenic mouse models of AD (Kaminari et al., 2017) and TrkB deletion accelerates and worsens the phenotype of these mice (Devi and Ohno, 2015) whereas TrkB agonists improve it (Devi and Ohno, 2012;Zhang et al., 2014). Alterations in the BDNF-TrkB system could account for memory deficits, neuronal cell death and synaptic plasticity alterations observed in AD (von Bohlen Und and von Bohlen, V, 2018). BDNF-TrkB associated downstream molecular pathways include PLCγ, ERK and Akt signaling. Interestingly, dysregulation of these pathways is able to modulate the levels of essential synaptic proteins such as PSD-95 and synaptophysin (Parsons et al., 2014;Robinet and Pellerin, 2011;Tartaglia et al., 2001;Yoshii and Constantine-Paton, 2014;Zhang et al., 2017), which in turn are altered in AD models

104 (Dorostkar et al., 2015;Yuki et al., 2014). Finally, altered BDNF-TrkB pathway could
105 also result in deficient adult neurogenesis in the hippocampus (Waterhouse et al., 2012),
106 which could in turn contribute to the memory loss in AD (Toda and Gage, 2017).

107 Several strategies have been proposed to produce/deliver BDNF to counteract
108 neurodegeneration. However, all of them are associated with deleterious secondary
109 effects or are not satisfactory enough (Lindvall et al., 2004). Important drawbacks are
110 the risk of tumorogenesis, insufficient cell survival in cell therapy, or invasiveness of
111 some delivery systems, as well as the lack of control on the production and delivery of
112 the neurotrophin since too high levels can be neurotoxic (Kells et al., 2008;Martinez-
113 Serrano and Bjorklund, 1996;Pineda et al., 2007;Rubio et al., 1999). Furthermore, these
114 strategies do not target specifically the diseased tissue or deliver appropriate levels of
115 the neurotrophin depending on the severity of the symptoms.

116 Astrocytes in Alzheimer disease are reactive at early stages, they have impaired
117 Ca^{2+} signaling, they regulate β-amyloid burden, and they influence synaptic plasticity
118 alterations also contributing to excitotoxicity (Acosta et al., 2017). Interestingly,
119 astrocytes normally express the BDNF protein although at lesser levels than neurons
120 (Fulmer et al., 2014;Giralt et al., 2010;Hong et al., 2016;Saha et al., 2006). Therefore,
121 engineered astrocytes could be good candidates to release neurotrophic factors. In fact,
122 genetically modified astrocytes have been used with positive results in some models of
123 neurodegeneration (Carpenter et al., 1997;Yoshimoto et al., 1995). This strategy could
124 be relevant for AD as the numbers of reactive astrocytes increases gradually as the
125 disease progress (Song et al., 2015). Moreover, astrogliosis has been shown to be one of
126 the specific hallmarks of disease progression in mouse models of AD (Oakley et al.,
127 2006). Because of this increase in astrocytes, and the fact that astrogliosis leads to
128 increased glial fibrillary acidic protein (GFAP) promoter activation, one would predict

that the use of this promoter as a self-regulator would provide neurotrophic support at the time when it is critically needed. Therefore, here we sought to investigate the role of BDNF from astrocytes in normal neuronal dendritic growth and whether this could be exploited to design advanced and conditional therapies in AD models.

Methods

Astrocyte/neurons co-cultures

Primary astrocyte cultures were obtained from P1 to P3 $BDNF^{+/+}$ and $BDNF^{-/-}$ mouse pups (Ernfors et al., 1994; IMSR Cat# EM:00247, RRID:IMSR_EM:00247) by hippocampal dissections. Extracted tissue was dissociated and placed in 25 cm^2 flasks in a MEM 1x conditioned media NM-15 (20% fetal bovine serum; Gibco-BRL, Renfrewshire, Scotland, UK; D-Glucose 90 mM; Buchs, Switzerland) with L-glutamine and Earle's salts (Gibco-BRL) and placed in an incubator at 37ºC with 5% CO_2. A tail biopsy was obtained from each pup for genotyping. After two passages cultures were purified by agitating in a shaker during 10 min at 400 rpm Medium with undesired floating cells was replaced and flasks were placed in an incubator for 2 h at 37ºC. Next, flasks were agitated again for 16–18 h at 250 rpm. Finally, medium with floating cells was replaced with new medium. Once astrocytes reached confluence, they were seeded in 24-well plaques and allowed to reach confluence. Then, one day before the addition of hippocampal neurons, astrocyte cultures were pre-incubated with neurobasal medium (GIBCO, Renfrewshire, Scotland, UK) containing 1 ml per 50 ml of B27 supplement (Gibco-BRL) and 50 ml of GlutaMAX (100x) (Gibco-BRL). Hippocampal neurons were prepared from E17 C57Bl/6J mouse embryos (pregnant mice from Charles River, Saint Germain Nuelles, France). The neuronal cell suspension was low density seeded

154 in the 24-well plaques already containing astrocytes (10,000 cells cm^2). Co-cultures
155 were fixed at DIV6 or DIV20 after neurons seeding to evaluate the number of dendrites
156 and dendritic spines respectively. Cultures collected at DIV20 were transfected 48 h
157 before cell fixation with Transfectine (Bio-Rad, Hercules, CA, USA) following the
158 manufacturer's instructions. Cells were transfected with a previously described
159 construct expressing GFP (Giralt et al., 2017) to allow dendritic spine density counting
160 in isolated hippocampal neurons.
161
162 *Quantitative (Q)-PCR assay*
163 Total RNA from astrocyte cultures (see avobe) and HEK293 cells was extracted using
164 the RNeasy® Lipid Tissue Mini Kit (QIAGEN, Maryland, USA). Total RNA (500 ng)
165 was used to synthesize cDNA using random primers with the High Capacity cDNA
166 Reverse Transcription Kit (Applied Biosystems, Cheshire, UK). The cDNA synthesis
167 was performed at 37 ºC for 120 min in a final volume of 20 µl according to
168 manufacturer's instructions. The cDNA was then analyzed by Q-PCR using the
169 following gene expression assays: 18S (NR_003286; Integrated DNA Technologies)
170 and BDNF (NM_001048139; Integrated DNA Technologies). Reverse-transcriptase
171 (RT) polymerase chain reaction was performed in 12-µl of final volume on 96-well
172 platesusing the Premix Ex Taq (Probe qPCR; Takara Biotechnology Inc., Kusatsu,
173 Shinga, Japan). Reactions included Segment 1: 1 cycle of 30 seconds at 95 ºC and
174 Segment 2: 40 cycles of 5 seconds at 95 ºC and 20 seconds at 60 ºC. All RT-PCR assays
175 were performed in duplicate and repeated for at least three independent experiments. To
176 provide negative controls and exclude contamination by genomic DNA, the RT was
177 omitted in the cDNA synthesis step, and the samples were subjected to the PCR reaction
178 in the same manner with each TaqMan® Gene Expression Assay. The RT-PCR data

were analyzed using the MxProTM Q-PCR analysis software version 3.0 (Stratagene). Quantification was performed with the Comparative Quantitation Analysis program of this software and using the 18S gene expression as internal loading control.

Immunocytochemistry and neuronal morphology assessment

Fixed cells were permeabilized in Triton X-100 0.5% (vol/vol) for 10 min and then blocking was performed with 10 g/L bovine serum albumin (BSA) in PBS for 1 h. Cells were incubated with a mouse monoclonal antibody for MAP2 (1:800, Sigma-Aldrich Cat# M1406, RRID:AB_477171) at 4°C overnight. After three washes with PBS, cells were incubated with the corresponding Cy3-coupled fluorescent secondary antibody (1:200; Jackson ImmunoResearch Labs Cat# 715-165-150, RRID:AB_2340813). After washing twice with PBS, the coverslips were mounted with Vectashield (Vector Laboratories Burlingam, UK). Hippocampal neuron staining was observed with a confocal SP5-II (see below)

Mouse lines

For this study we used the transgenic mouse line 5xFAD (MMRRC Cat# 034840-JAX, RRID:MMRRC_034840-JAX). 5xFAD mice over-express the 695-amino acid isoform of the human amyloid precursor protein (APP695) carrying the Swedish, London, and Florida mutations under the control of the murine Thy-1 promoter. In addition, they express human presenilin-1 (PSEN-1) carrying the M146L/L286V mutation, also under the control of the murine Thy-1 promoter (Oakley et al., 2006). We crossed 5xFAD mice with the previously generated pGFAP-BDNF mice (Giralt et al., 2010) to obtain 5xFAD mice that over-express BDNF under the GFAP promoter (5xF:pGB mice). For

astrocyte cultures we used P1-P3 BDNF$^{+/+}$ and BDNF$^{-/-}$ mice (Ernfors et al., 1994; IMSR Cat# EM:00247, RRID:IMSR_EM:00247). Mouse genotyping for pGFAP-BDNF, 5xFAD and BDNF$^{-/-}$ mice was carried out from a tail biopsy, as previously described (Giralt et al., 2009;Giralt et al., 2010;Oakley et al., 2006), by Charles River services. The animals were housed with access to food and water *ad libitum* in a colony room kept at 19–22ºC and 40–60% humidity, under a 12:12 h light/dark cycle. Experimental animals were all males and used at 8 months of age and in accordance with the ethical guidelines (Declaration of Helsinki and NIH, publication no. 85-23, revised 1985, European Community Guidelines, and French Agriculture and Forestry Ministry guidelines for handling animals, decree 87849, license A 75-05-22) and approved by the local ethical committee.

Western blot

Mice were deeply anesthetized in a CO_2 chamber, the brains quickly removed, hippocampus dissected out, frozen in dry ice, and stored at -80ºC until use. Briefly, tissue was sonicated in 250 mL of lysis buffer (PBS, 1% Nonidet P40 [vol/vol], 1 g/L SDS, 5 g/L sodium deoxycholate, protease inhibitors cocktail 1:1,000 (Sigma), and 2 g/L sodium orthovanadate) and centrifuged at 12,000 rpm for 20 min and the pellet was discarded. Proteins (15 mg) from hippocampal or cortical tissue was analyzed by SDS-polyacrylamide gel electrophoresis (7.5% acrylamide, wt/vol) and transferred to nitrocellulose membranes (Millipore, Bedford, MA). Membranes were blocked in TBS-T (150 mM NaCl, 20 mM Tris-HCl, pH 7.5, 0.05% [vol/vol] Tween 20) with 50 g/L non-fat dry milk and 50 g/L BSA. Immunoblots were probed with anti-GFAP (1:1,000, Agilent Cat# Z0334, RRID:AB_10013382), anti-BDNF (1:1000, Santa Cruz Biotechnology Cat# sc-546, RRID:AB_630940), anti-Akt (1:1000, Cell Signaling

Technology Cat# 9272, RRID:AB_329827), anti-ERK (1:1000, Cell Signaling Technology Cat# 4695, RRID:AB_390779), anti-PLCγ (1:1000, Cell Signaling Technology Cat# 2822, RRID:AB_2163702), anti-phosphor-Akt (1:1000, Cell Signaling Technology Cat# 4056, RRID:AB_331163), anti-phosphor-ERK (1:1000, Cell Signaling Technology Cat# 9101, RRID:AB_331646), anti-phosphor-PLCγ (1:1000, Cell Signaling Technology Cat# 2821, RRID:AB_330855) or anti-alpha-Tubulin (1:10,000, Sigma-Aldrich Cat# T9026, RRID:AB_477593). All blots were incubated overnight at 4ºC with shaking, in the presence of the primary antibody in PBS with 0.2 g/L sodium azide. After several washes in TBS-T, blots were incubated with anti-rabbit IgG IRdye800CW-coupled or anti-mouse IgG IRdye700DX-coupled antibodies (1/2,000, Rockland Immunochemicals, USA) and signal detected by the Odyssey system (Li-Cor) and analyzed using ImageJ.

Golgi staining, spine counting and morphological analysis

Fresh brain hemispheres were processed following the Golgi-Cox method as described elsewhere (Giralt et al., 2017). Essentially, mouse brain hemispheres were incubated in the dark for 21 days in filtered dye solution (10 g L^{-1} $K_2Cr_2O_7$, 10 g L^{-1} $HgCl_2$ and 8 g L^{-1} K_2CrO_4). The tissue was then washed 3 x 2 min in water and 30 min in 90% EtOH (vol/vol). Two hundred-µm sections were cut in 70% ethanol (EtOH) on a vibratome (Leica) and washed in water for 5 min. Next, they were reduced in 16% (vol/vol) ammonia solution for 1 h before washing in water for 2 min and fixation in 10 g l^{-1} $Na_2S_2O_3$ for 7 min. After a 2-min final wash in water, sections were mounted on superfrost coverslips, dehydrated for 3 min in 50%, then 70, 80, and 100% EtOH, incubated for 2 x 5 min in a 2:1 isopropanol:EtOH mixture, followed by 1 x 5 min in pure isopropanol and 2 x 5 min in xylol. Bright-field images of Golgi-impregnated

stratum radiatum dendrites from hippocampal CA1 pyramidal neurons were captured with a Nikon DXM 1200F digital camera attached to a Nikon Eclipse E600 light microscope (x100 oil objective). Only fully impregnated pyramidal neurons with their soma found entirely within the thickness of the section were used. Image z-stacks were taken every 0.2 mm and at 1,024 x 1,024 pixel resolution, yielding an image with pixel dimensions of 49.25 x 49.25 mm. Z-stacks were deconvolved using the Huygens software (Scientific volume imaging, Hilversum, the Netherlands) to improve voxel resolution and to reduce optical aberration along the z axis. The total number of spines counting, and their morphology categorization was performed by using the Neuronstudio freeware (NeuronStudio, RRID:SCR_013798). At least 60 dendrites per group from at least five mice per genotype were counted. For spine morphology analysis we analyzed between 2,000-3000 spines (500 spines per mouse from 5 mice per group). Each spine was categorized as having or not having a neck. Spines were defined as stubby if they did not contain a visible neck. Spines with necks were separated into thin and mushroom spines based on head width. Filopodia, defined as protrusions 1.5 microns in length without a head, were excluded from the analysis of spine subtypes. Spines with heads less than the average width were categorized as thin, and those with heads greater than the average width were categorized as mushroom as previously described (Giralt et al., 2017). From these measures, the percentage of the various spine types were obtained. Picture acquisition and subsequent analysis were performed independently by two investigators blind to genotypes and results were then pooled. Overall differences between the results were minor.

Tissue fixation and immunofluorescence

Animals were deeply anesthetized with pentobarbital (60 mg/kg) and intracardially perfused with a 4% (wt/vol) paraformaldehyde solution in 0.12 M sodium phosphate, pH 7.2. Brains were removed and post-fixed overnight in the same solution, cryoprotected with 300 g/L sucrose in 20 mM sodium phosphate, pH 7.5, 150 mM NaCl (PBS) with 0.2 g/L sodium azide and frozen in dry ice-cooled isopentane. Serial coronal sections (30 microns) obtained with a cryostat were processed for immunohistochemistry as free-floating sections. They were washed three times in PBS, permeabilized 15 min by shaking at room temperature with PBS containing (vol/vol) 0.3% Triton X-100 and 3% normal goat serum (Pierce Biotechnology, Rockford, IL). After three washes, brain sections were incubated overnight (o.n.) by shaking at 4ºC with antibodies for anti-PSD-95 (1:500, Millipore Cat# MAB1596, RRID:AB_2092365), anti-synaptophysin (1:500, Synaptic Systems Cat# 101 011, RRID:AB_887824) or anti-phosphor-TrkB^{Y816} (1:350, Abcam Cat# ab75173, RRID:AB_1281172) in PBS with 0.2 g/L sodium azide. After incubation with primary antibody, sections were washed three times and then placed 2 h on a shaking incubator at room temperature with the subtype-specific fluorescent secondary Alexa-Fluor 488 anti-rabbit (1:250, Thermo Fisher Scientific Cat# A32731, RRID:AB_2633280) or anti-mouse 555 (1:250, Thermo Fisher Scientific Cat# A32727, RRID:AB_2633276). No signal was detected in control sections incubated in the absence of the primary antibody.

Confocal imaging and analysis

Dorsal hippocampus in fixed tissue and fixed primary cultures were imaged using a Leica Confocal SP5-II at the *Institut du Fer à Moulin* Cell and Tissue Imaging facility, with a 40x or 63x numerical aperture lens with 5× digital zoom and standard (1 Airy disc) pinhole (1 AU) and frame averaging (3 frames per *z*-step) were held constant

throughout the study. Confocal *z*-stacks were taken every 0.2 µm for *in vitro* experiments and every 2 µm for *in vivo* experiments, and at 1,024 × 1,024 pixel resolution. The *in vitro* Sholl analysis, the dendritic spine counting, the *in vivo* analysis of PSD95- and synaptophysin-positive clusters and the co-localization of double labeled PSD-95/phospho-TrkB^{Y816}-positive clusters were analyzed with the freeware ImageJ (ImageJ, RRID:SCR_003070). Briefly, for *in vivo* imaging analysis, for each mouse, at least 3 slices of 30 µm containing dorsal hippocampal tissue were analyzed. Up to 3 representative images, from CA1-stratum radiatum layer, were obtained from each slice. For the *in vitro* analysis, in the Sholl experiment we evaluated 45-60 neurons, all of them MAP2-positive from 3 different cultures. To estimate the density of dendritic spines, 31-41 dendrites from MAP2-positive neurons (1-2 dendrites/neuron) from 3 different cultures were counted.

Electronic microscopy

Mice were transcardially perfused with a solution containing 4% paraformaldehyde and 0.1% glutaraldehyde made up in 0.1 M phosphate buffer (PB), pH 7.4. Brains were then immersed in the same fixative for 12 h at 4°C.Tissue blocks containing the hippocampus were dissected and washed in 0.1 M PB, cryoprotected in 100 and 200 g/L sucrose in 0.1 M PB, freeze-thawed in isopentane and liquid nitrogen. Samples were postfixed in 2.5 % glutaraldehyde made up in 0.1 M phosphate buffer for 20 min, washed and treated with 2% osmium tetroxide in PB for 20 min. They were dehydrated in a series of ethanol and flat embedded in epoxy resin (EPON 812 Polysciences). After polymerization, blocks from the CA1 region were cut at 70 nm thickness using an ultramicrotome (Ultracut E Leica). Sections were cut with a diamond knife, picked up

on formvar-coated 200 mesh nickel grids. For etching resin and remove osmium, sections were treated with saturated aqueous sodium periodate ($NaIO_4$). They were then observed with a Philips (CM-100) electron microscope at the *Institut du Fer à moulin* Cell and Tissue Imaging facility. Digital images were obtained with a CCD camera (Gatan Orius). To test method specificity of the immunostaining procedure, the primary antibody was omitted. In ultrathin sections the density of synaptic vesicles was calculated by counting the number of vesicles within a defined presynaptic area. The area of postsynaptic densities was also evaluated. All these calculations were performed by using the ImageJ.

Behavioral tests

To analyze mouse anxiety, we used the elevated **plus maze** paradigm. Briefly, the plus maze was made of plastic and consisted of two opposing 30 × 8 cm open arms, and two opposing 30 × 8 cm arms enclosed by 15 cm-high walls. The maze was raised 50 cm from the floor and lit by dim light. Each mouse was placed in the central square of the raised plus maze, facing an open arm and its behavior was scored for 5 min. At the end of each trial, any defecation was removed, and the apparatus was wiped with 30% ethanol. We recorded the time spent in the open arms, which normally correlates with low levels of anxiety. Animals were tracked and recorded with SMART junior software (Panlab, Spain).

To check spontaneous locomotor activity, we used the **open field**. Briefly, the apparatus consisted of a white square arena measuring 40 x 40 x 40 cm in length, width and height respectively. Dim light intensity was 60 lux throughout the arena. Animals were placed in the arena center and allowed to explore freely for 30 min. Spontaneous locomotor activity was measured. At the end of each trial, any defecation was removed,

and the apparatus was wiped with 30% ethanol. Animals were tracked and recorded with SMART junior software (Panlab, Spain).

The **novelty-suppressed feeding** (NSF) measured the mice aversion to eat in a novel environment. This test assesses stress-induced anxiety by measuring the latency of an animal to approach and eat a familiar food in an aversive environment. For this task mice were food-restricted for a period of 24 h. After food restriction, the animals were placed in a large, brightly lit, open field. A piece of white filter paper was placed in the center of the arena with a small piece of rodent chow. The time to approach and eat a pellet of food located in the center of the arena was measured and used to evaluate anxiety-like behavior.

The **forced swimming** test was used to evaluate behavioral despair. Animals were subjected to a 6-min trial during which they were forced to swim in an acrylic glass cylinder (35 cm of height x 20 cm of diameter) filled with water, and from which they could not escape. The time that the test animal spent in the cylinder without making any movements beyond those required to keep its head above water was measured.

The spontaneous alternation performance was tested using a symmetrical **Y-maze**. Each mouse was placed in the center of the Y-maze and could explore freely through the maze during an 8-min session. The sequence and total number of arms entered were recorded. Arm entry was complete when the hind paws of the mouse had been completely placed in the arm. Percentage alternation is the number of triads containing entries into all three arms divided by the maximum possible alternations (the total number of arms entered minus 2) × 100. As the re-entry into the same arm was not counted for analysis, the chance performance level in this task was 50% in the choice

between the arm mice visited more recently (non-alternation) and the other arm visited less recently (alternation).

The **novel object location** (NOL) memory task evaluates spatial memory and is based on the ability of mice to recognize when a familiar object has been relocated. Exploration took place in an open-top arena with quadrangular form (45 × 45 cm). The light intensity was 40 lux throughout the arena. Mice were first habituated to the arena in the absence of objects (1 day, 30 min). Some distal cues were placed throughout the procedure. On the third day during the acquisition phase mice could explore 2 duplicate objects (A1 and A2), which were placed close to the far corners of the arena for 10 minutes. After a delay of 24 h, 1 object was placed in the diagonally opposite corner. Thus, both objects in the phase were equally familiar, but 1 was in a new location. The position of the new object was counterbalanced between mice. Animals were tracked and recorded with SMART Junior software.

For the **passive avoidance** (light-dark) paradigm we conducted the experiments in a 2-compartment box, where 1 compartment was dimly lit (20 lux) and preferable to a rodent and the other compartment was brightly lit (200 lux); both chambers were connected by a door (5 cm × 5 cm). During training, mice were placed into the aversive brightly lit compartment, and upon the entry into the preferred dimly lit compartment (with all 4 paws inside the dark chamber), mice were exposed to a mild foot shock (2-second foot shock, 1 mA intensity). The latency of mice to enter into the dark chamber was recorded. Twenty seconds after receiving the foot shock, mice were returned to the home cage until testing. After 24 h (long-term memory), animals were tested for retention. In the retention test, mice were returned to the brightly lit compartment again, and the latency to enter the shock paired compartment (dark chamber) was measured (retention or recall latency). Ten minutes was used as a time cutoff in the retention test.

The animals that learned the task would avoid the location previously paired with the aversive stimulus and showed a greater latency to enter it.

In vivo electrophysiological recordings

Animals were anesthetized with 0.8-1.5% isoflurane (Astra Zeneca, Madrid, Spain) delivered via a special mask (Cibertec, Madrid, Spain). Once anaesthetized, animals were implanted with bipolar stimulating electrodes aimed at the right Schaffer collateral-commissural pathway of the dorsal hippocampus (2 mm lateral and 1.5 mm posterior to bregma; depth from brain surface, 1.0-1.5 mm; Paxinos and Frankin, 2013) and with a recording electrode aimed at the ipsilateral *stratum radiatum* underneath the CA1 area (1.2 mm lateral and 2.2 mm posterior to bregma; depth from brain surface, 1.0-1.5 mm; Paxinos and Franklin, 2013). Stimulating and recording electrodes were made of 50 µm, Teflon-coated tungsten wire (Advent Research Materials, Eynsham, UK). The final location of the recording electrode in the CA1 area was determined following the field potential depth profile evoked by paired (40-ms interval) pulses presented to the ipsilateral Schaffer collateral pathway (Gruart et al., 2006). Two bare silver wires were affixed to the skull as ground. Electrodes were connected to a 6-pin socket (RS-Amidata, Madrid, Spain) that was latterly fixed with dental cement to the cranial bone. After surgery, each animal was kept in an independent cage with free access to food and water for the rest of the experiment.

Recording sessions were started one week after surgery. Electrophysiological recordings were performed using Grass P511 differential amplifiers with a bandwidth of 0.1-10 KHz (Grass-Telefactor, Warwick, RI, USA). Electrical stimulation was provided by a CS-220 stimulator across CS-220 isolation units (Cibertec). For input/output curves, monosynaptic field excitatory postsynaptic potentials (fEPSP) were evoked in

425 the CA1 area by single (100 μs, square, and negative-positive) pulses applied to
426 Schaffer collaterals. These pulses were presented at increasing intensities ranging from
427 20 μA to 400 μA, in steps of 20 μA. In order to avoid interactions with the preceding
428 stimuli, an interval of 30 s was allowed between each pair of pulses (Madronal et al.,
429 2007).

430 For the characterization of the paired-pulse facilitation at the CA3-CA1 synapse,
431 we used the same type of pulses indicated above, but presented in pairs at increasing
432 inter-pulse intervals (10, 20, 40, 100, 200, and 500 ms). For each animal, the stimulus
433 intensity was set at 30-40% of the intensity necessary for evoking a maximum fEPSP
434 response (Gruart et al., 2006; Gureviciene et al., 2004). Intervals between pairs of pulses
435 were set at ~ 30 s, to avoid unwanted interactions evoked by pre- or post-synaptic
436 mechanisms.

437 LTP experiments were also carried out in alert behaving animals. Field EPSPs
438 were evoked at the CA3-CA1 synapse for 15 min prior to LTP induction. For this,
439 single pulses were presented at a rate of 3 per min. The stimulus intensity was set at 30-
440 40% of the intensity necessary for evoking a maximum fEPSP response—namely, well
441 below the threshold for evoking a population spike (Gruart et al., 2006;Madronal et al.,
442 2007). For LTP induction, each animal was subjected to a high-frequency stimulation
443 (HFS) protocol consisting of five 200 Hz, 100 ms trains of pulses at a rate of 1 per s.
444 This protocol was presented six times, at intervals of 1 min. The HFS protocol used here
445 (combining low intensity values and a total of 600 electric shocks) allowed us to evoke
446 LTP lasting > 2-3 days, without the appearance of abnormal spikes in EEG recordings
447 and/or overt epileptic seizures (Madronal et al., 2009). Following the HFS session,
448 animals were stimulated again with single pulses applied for 60 min at the same rate of

3 per min. Additional 30-min recordings of fEPSPs were repeated for 3 days following the HFS session.

Experimental design and statistical analysis

All data are expressed as mean ± SEM. Statistical analysis were performed using the unpaired two-sided Student's t-test (95% confidence), one-way ANOVA with the Tukey's as *post hoc* tests, two-way ANOVA with the Bonferroni's *post hoc* test as appropriate and indicated in the figure legends. Values of $p < 0.05$ were considered as statistically significant.

All experiments in this study were blinded and randomized. All mice bred for the experiments were used for preplanned experiments and randomized to experimental groups. Visibly sick animals were excluded before data collection and analysis. Data were collected, processed and analyzed randomly. The experimental design and handling of mice were identical across experiments. Littermates were used as controls with multiple litters (3– 5) examined per experiments. All mice were bred in the *Institut du Fer à Moulin* Animal Facility.

Results

Astrocytes BDNF production regulates cultured hippocampal neurons morphology and dendritic spine density

Although BDNF is mainly produced in neurons, it is also localized in astrocytes (Giralt et al., 2010;Saha et al., 2006). We verified that this was the case in our experimental conditions using RT-PCR to detect BDNF transcripts (3745 ± 1125% increase, $p = 0.0468$) (Fig. 1*A*). However, the precise role of BDNF from astrocytes in neuronal

474 function is still unclear. We evaluated whether BDNF derived from astrocytes was
475 physiologically relevant for neuronal dendrite morphology. We cultured primary
476 astrocytes from mouse pups lacking the BDNF gene ($BDNF^{-/-}$ pups) or wild type (wt)
477 littermates as a control ($BDNF^{+/+}$ pups). After astrocyte 100% confluence, we seeded
478 primary wt neurons at E17 on the top of the astrocyte monolayer (Fig. 1*B*). Then, some
479 astrocyte-neuron co-cultures were fixed at 6 DIV to evaluate the morphological
480 characteristics of the imaged neurons stained for MAP2 by using the Sholl analysis
481 (Fig. 1*C*). The results indicated that the number of intersections in wt neurons grown on
482 $BDNF^{-/-}$ astrocytes were reduced as compared with wt neurons on $BDNF^{+/+}$ astrocytes
483 (Fig. 1*D*). We fixed other astrocyte-neuron co-cultures at 20 DIV, transfected 48 h prior
484 to fixation with a GFP-expressing construct (see Material and Methods). We thus were
485 able to evaluate spine density in isolated MAP2-positive neurons. We observed that the
486 number of spines in wt neurons co-cultured with $BDNF^{-/-}$ astrocytes was decreased as
487 compared to neurons co-cultured with $BDNF^{+/+}$ astrocytes (-0.2555 ± 0.046 decrease, p
488 < 0.0001) (Fig. 1*E*). These results reveal a crucial role of BDNF released from
489 astrocytes in the modulation of neurons, particularly in dendrite and spine development,
490 in co-culture conditions. They provide a rationale for the use of astrocytes to over-
491 express BDNF in brain locations with high levels of pathology in AD.

492

493 **Generation and characterization of the 5xFAD mice over-expressing BDNF under**
494 **the GFAP promoter**

495 To test the potential role of astrocytes-derived BDNF in an AD mouse model, we then
496 took advantage of mice that over-express BDNF under the control of the GFAP
497 promoter (pGFAP-BDNF mice; (Giralt et al., 2010)). In these mice BDNF production

and delivery is increased in neuropathological conditions accompanied by astrogliosis (Giralt et al., 2010;Giralt et al., 2011). We crossed pGFAP-BDNF mice with the 5xFAD transgenic mouse model of AD to create 5xF:pGB mice. The 5xFAD mice develop severe amyloid pathology and associated astrogliosis at 1.5-2 months of age, before the onset of the cognitive deficits (observed at 4 months of age; (Oakley et al., 2006)). A significant decrease in BDNF levels is also observed in 5xFAD mice (Hongpaisan et al., 2011). We predicted that this decrease would be prevented in the 5xF:pGB double transgenic mice. To test this hypothesis, we analyzed BDNF hippocampal levels in wt, pGFAP-BDNF, 5xFAD, and 5xF:pGB mice at 8 months of age, when their phenotype is clear. At this age astrogliosis was obvious throughout the hippocampus, as evidenced by immunofluorescence (Fig. 2*A*) and western blot (146 ± 18 increase, $p < 0.001$) (Fig. 2*B-C*). As expected, BDNF levels were reduced (-58 ± 17 decrease, $p < 0.05$) in the hippocampus of 5xFAD mice as compared with wt mice (Fig. 2*B* and *D*). Interestingly, BDNF levels in the hippocampus of 5xF:pGB mice were undistinguishable from those in wt mice indicating a full recovery of BDNF protein levels in this group of mice. We next studied whether such recovery correlated with an improvement in the BNDF-TrkB downstream signaling. We performed western blot analyses to measure total and phosphorylated levels of ERK, Akt and, PLCγ, which are key proteins in the three major signaling pathways downstream of BDNF-TrkB (Gupta et al., 2013). Total levels of ERK, Akt and PLCγ were similar in all the four groups of mice (Fig. 2*E*). Phosphorylation levels of ERK threonine/tyirosine 202/204 and PLCγ tyrosine 783 were decreased in the hippocampus of 5xFAD mice ($ERK^{T202/Y204}$: -69 ± 8.5 decrease, $p < 0.001$; $PLC\gamma^{Y783}$: -40 ± 17 decrease, $p < 0.05$), whereas Akt serine 308 phosphorylation was not significantly affected (Fig. 2*E-F*). In 5xF:pGB mice phosphorylation of ERK and PLCγ was like that in wt mice. Interestingly, in 5xF:pGB

mice the phosphorylated levels of ERK and PLCγ were similar to those in wt mice. No changes in these phosphoproteins were observed in the wild type mice expressing the pGFAP-BDNF transgene (Fig. 2*E, F*) supporting the specificity of the astrocyte-dependent BDNF expression. These results indicate that the 5xF:pGB mice develop a significant astrogliosis, which, in turn, induces an over-production of BDNF from astrocytes preventing the loss of BDNF/TrkB function due to the effects of APP695 and PSEN-1 transgenes. Furthermore, normalization of BDNF levels in the 5xF:pGB mice was accompanied by a complete restoration of BDNF-TrkB downstream signaling.

Rescue of memory alterations in 5xF:pGB mice

The 5xFAD transgenic mice display a strong phenotype with a relatively fast time course as compared with other AD mouse models. At 8 months of age they display decreased locomotor activity, altered performance in the elevated plus maze, and memory deficits in hippocampal-related tasks such as the Y-maze and the novel object location (Devi and Ohno, 2015;Grinan-Ferre et al., 2016;Oakley et al., 2006;Schneider et al., 2015). The passive avoidance, which is also affected in other mouse models of AD (Webster et al., 2014), has not been reported in 5xFAD, to our knowledge. Furthermore, AD patients exhibit high comorbidity with depressive symptoms (Webster et al., 2014) and depressive behaviors have been reported at least in one mouse model of AD (Filali et al., 2009).

To evaluate the potential beneficial effects of reactive astrocytes-targeted BDNF expression in 5XFAD mice, we characterized all these behavioral parameters. We first evaluated the basal locomotor activity and anxiety in the open field in wt, pGFAP-BDNF, 5xFAD, and 5xF:pGB mice. All groups of mice displayed a similar initial habituation and comparable levels of locomotor activity (Fig. 3*A*) and time spent in the

548 center (Fig. 3*B*). Next, we investigated anxiety by performing the elevated plus maze
549 and the novelty-suppressing feeding (NSF) tests. In the elevated plus maze both 5xFAD
550 mice (18.45 ± 6.6 increase, $p < 0.05$) and 5xF:pGB mice (23.50 ± 6.92 increase, $p <$
551 0.01) spent more time in the open arms than wt and pGFAP-BDNF mice (Fig. 3*C*), but
552 there were no differences between 5xFAD and 5xF:pGB mice. In the NSF the mice
553 from all four groups showed similar latencies to feed in the aggressive environment
554 (Fig. 3*D*). We also tested the behavioral resignation in the four groups of mice by
555 performing the forced swimming test (FST). The amount of time during which the mice
556 were swimming trying to escape from the water was similar in all mice, independently
557 of their genotype (Fig. 3*E*). These results indicate that 5XFAD mice displayed only
558 minor anxiety or mood related alterations, with only an apparent decrease in anxiety in
559 the elevated plus maze which was not modified by BDNF overexpression.

560 We next studied memory in these mice. First, we evaluated spatial memory in
561 the novel object location test (NOL), which is based on the ability of rodents to
562 recognize when a familiar object has been relocated. After habituation to the open field
563 arena, mice were trained in the presence of 2 identical objects (A1 and A2) and spatial
564 memory was assessed 24 h later by displacing one of the two objects. 5xFAD mice
565 exhibited a significantly lower preference for the displaced object compared (1.877 ±
566 5.64 n.s. between OL and NL) with either wt or pGFAP-BDNF mice (Figure 3*F*). The
567 spatial memory deficit was prevented in the 5xF:pGB mice (Figure 3*F*). Next, mice
568 were tested in the spontaneous alternation Y-maze paradigm that assesses spatial
569 working memory (Lalonde, 2002). The spontaneous alternation behavior relies on the
570 tendency of mice to enter a less recently visited arm compared with the other one. Wild
571 type and pGFAP-BDNF mice displayed a spontaneous alternation, whereas the arm
572 choice was decreased to 50% (chance levels) in the 5xFAD mice (-12.70 ± 3.27

573 decrease, $p < 0.01$) (Fig. 3*G*). The spontaneous alternation was restored to wt control
574 levels in 5xF:pGB mice. Finally, we examined associative memory in the passive
575 avoidance task, based on the association formed between an electrical foot shock and a
576 spontaneously preferred specific environmental context (darkness vs. light). Latency to
577 step-through during the training session was similar between genotypes (Fig. 3*H*).
578 However, in the testing session, although all genotypes showed a significant increase in
579 the latency to enter the dark compartment 24 h after receiving an electrical shock (wt:
580 255 ± 39 increase, $p < 0.001$; pGFAP-BDNF: 192 ± 32 increase, $p < 0.001$; 5xFAD 78.8
581 ± 28 increase, $p < 0.05$; 5xF:pGB: 145 ± 35 increase $p < 0.001$), this latency was shorter
582 in mutant 5xFAD mice as compared with wt (-178 ± 34 decrease, $p < 0.001$) or pGFAP-
583 BDNF mice (-117.70 ± 30 decrease, $p < 0.01$) (Fig. 3*H*). This alteration was absent in
584 double mutant 5xF:pGB mice (Fig. 3*H*). The results of the NOL, spontaneous
585 alternation and passive avoidance tests demonstrate that targeted increased expression
586 of BDNF prevented several memory deficits in 5xFAD mice.
587
588 **Normalization of BDNF levels in double mutant 5xF:pGB mice does not prevent**
589 **plaque formation and neurogenesis deficits**
590 To test whether the restoration of BDNF levels modulated β-amyloidosis in 8-month old
591 5xFAD mice toluidine blue staining was performed to determine the number of plaques
592 in the hippocampus and prefrontal cortex of 5xFAD and 5xF:pGB mice (Fig. 4*A*). The
593 cortical plaque load in 5xF:pGB mice was indistinguishable from that in age-matched
594 5xFAD control mice. However, in the hippocampus we detected an increase in the
595 number of plaques in 5xF:pGB mice compared to 5xFAD mice (0.3507 ± 0.0469
596 increase, $p = 0.017$) (Fig. 4*B*). We hypothesized that the size of the plaques could be
597 different between genotypes indicating different dynamics in β-amyloidosis. To test this

598 possibility, we characterized the plaques in the hippocampus of 5xFAD and 5xF:pGB
599 mice by using electron microscopy (Fig. 4*C*). Ultrastructural analysis revealed that
600 hippocampal plaques in 5xF:pGB mice were visually more compact but significantly
601 smaller than the plaques in 5xFAD mice (-131 ± 27 decrease, $p = 0.015$) (Fig. 4*C-D*),
602 supporting the hypothesis that β-amyloid accumulation in 5xF:pGB mice is different
603 compared to that in 5xFAD mice. Since findings on hippocampal plaques quantification
604 appeared inconsistent with memory improvements, we then evaluated the rate of
605 newborn cells in the dentate gyrus, whose deficits have been previously reported to be
606 associated with cognitive impairments (Moon et al., 2014). We counted the number of
607 Ki67-positive cells in the dentate gyrus of the 4 groups of mice. A significant decrease
608 in the number of newborn cells was observed in the dentate gyrus of both 5xFAD (-5 ±
609 1.69 decrease, $p < 0.05$) and 5xF:pGB (-5.26 ± 1.84 decrease, $p < 0.05$) mice as
610 compared with wt or pGFAP-BDNF mice (Fig. 4*E* and *F*). These data indicate that
611 normalizing BDNF levels in 5xF:pGB mice is not enough to prevent the alterations in
612 neurogenesis observed in 5xFAD mice.
613
614 **Normalization of BDNF levels in double mutant 5xF:pGB mice restore dendritic**
615 **spines and synaptic alterations**

616 Because BDNF normalization did not improve neuropathological hallmarks in 5xFAD
617 mice including astrogliosis (Fig. 2*A-C*), plaque number (Fig. 4*A-B*) and neurogenesis
618 deficit (Fig. 4*E-F*) we assumed that phenotypic improvements observed in 5xF:pGB
619 mice could be related with synaptic changes. To test this hypothesis, we performed
620 Golgi staining in two different brain regions in all 4 genotypes at the age of 8 months to
621 examine dendritic spine density and morphology in pyramidal neurons. We examined
622 the cortical layer V in the prefrontal cortex and the *stratum radiatum* of CA1. First, we

observed that spine density in secondary dendrites of cortical pyramidal neurons was significantly decreased in 5xFAD mice as compared with wt mice (-0.231 ± 0.034 decrease, $p < 0.001$) (Fig. 5*A-B*). This decrease was partially rescued in 5xF:pGB mice (-0.089 ± 0.036 decrease, $p < 0.05$) (Fig. 5*A-B*). Then, we analyzed spine morphology and the density of the three different spine types (mushroom, thin and stubby) in the same pyramidal neurons (Fig. 5*C*). No differences were observed in the density of stubby spines, whereas thin spines were markedly decreased in 5xFAD mice (-0.108 ± 0.021 decrease, $p < 0.001$) and completely recovered in 5xF:pGB mice (Fig. 5*C*). In contrast, mushroom spines were decreased equally in 5xFAD (-0.098 ± 0.021 decrease, $p < 0.001$) and in 5xF:pGB (-0.067 ± 0.023 decrease, $p < 0.05$) mice compared with wt and pGFAP-BDNF mice. These results revealed that overexpression of astrocytic BDNF in 5xF:pGB mice specifically rescued thin spines but not mushroom spines in the prefrontal cortex.

Next, we examined the same parameters in CA1 pyramidal neurons in the four genotypes. Spine density was decreased in 5xFAD mice as compared with wt mice (-0.132 ± 0.046 decrease, $p < 0.05$) and this decrease was rescued in 5xF:pGB mice (Fig. 5*D-E*). When we analyzed spine morphology, we detected a small decrease in stubby spine density only in 5xF:pGB as compared with wt mice (-0.076 ± 0.048 decrease, $p < 0.05$) whose meaning is uncertain (Fig. 5*F*). In contrast, a clear decrease in thin spines density was observed in 5xFAD as compared with wt mice (-0.100 ± 0.026 decrease, $p < 0.01$) that was rescued in 5xF:pGB mice (Fig. 5*F*). Finally, no changes in the density of mushroom spines were detected in any group. These results show that the main alteration in both prefrontal cortex and hippocampal CA1 region was a decrease in thin spines in 5xFAD mice which was rescued in 5xF:pGB mice.

To explore changes in excitatory synapses likely associated with spine alterations we evaluated pre- and post-synaptic markers. We examined the number of positive clusters for PSD-95 and synaptophysin, which are post- and pre-synaptic markers, respectively, previously reported to be decreased in 5xFAD mice, correlating with cognitive decline (Giralt et al., 2018;Yang et al., 2015). We analyzed these two markers in CA1 *stratum radiatum* of 8-month mice. As expected, the number of PSD-95-positive puncta was decreased in 5xFAD as compared to wild type mice (-754 ± 125 decrease, $p < 0.001$) (Fig. 6*A-B*). This decrease was rescued in 5xF:pGB mice (Fig. 6*A-B*). The number of synaptophysin-positive puncta was also decreased in CA1 *stratum radiatum* of 5xFAD as compared to wt mice (-685 ± 190 decrease, $p < 0.05$) (Fig. 6*C-D*). Synaptophysin puncta were recovered in 5xF:pGB mice. Altogether, these results suggest that the behavioral improvement observed in 5xF:pGB mice compared with 5xFAD mice was accompanied by an improvement in the clusters of pre- and post-synaptic markers, indicative of actual synapses. Additionally, we evaluated whether these changes were associated with direct TrkB-mediated signaling in neurons. To do so, we counted the number of double-labeled PSD-95/phospho-TrkB^{Y816}-positive puncta in the CA1 *stratum radiatum* of 8-month mice. We observed that 5xFAD mice displayed a reduction of double labeled PSD-95/phospho-TrkB^{Y816}-positive puncta in the *stratum radiatum* (-65 ± 20 decrease, $p < 0.05$) whereas such parameter was fully recovered in 5xF:pGB mice (Fig. 6*E-F*), indicating that 5xF:pGB mice improvements were associated to a TrkB-dependent signaling recovery in neurons. Next, to further examine pre- and post-synaptic changes we performed electronic microscopy experiments and analyzed the post-synaptic density (PSD) area and the number of pre-synaptic vesicles per synapse, in the CA1 *stratum radiatum* of the 4 groups of mice at 8 months. We observed no alteration of the PSD area in 5xFAD mice but an unexpected

672 increase in pGFAP-BDNF controls (0.0059 ± 0.00089 increase, $p < 0.001$) (Fig. 6*G-H*).
673 Conversely, the number of pre-synaptic vesicles per synapse was significantly
674 decreased in 5xFAD mice (-5.088 ± 1.046 decrease, $p < 0.001$) but was completely
675 rescued in 5xF:pGB mice (Fig. 6*G, I*). These results on spines, synaptic markers
676 clusters, and synaptic vesicles suggest that the cognitive improvements observed in
677 5xF:pGB mice resulted from synaptic improvements.
678
679 ***In vivo* study of electrophysiological properties of the CA3-CA1 synapses in**
680 **5xF:pGB mice**
681 To determine whether the rescue of histological alterations following BDNF astrocytic
682 expression was associated with functional improvements, we studied the *in vivo*
683 electrophysiological properties of hippocampal circuits in the four groups of mice. We
684 recorded input/output curves, paired-pulse facilitation, and LTP evoked at the CA3-
685 CA1 synapses (Fig. 7*A-C*).
686 We first analyzed the response of CA1 pyramidal neurons to single pulses of
687 increasing intensity (0.02-0.4 mA) presented to the ipsilateral Schaffer collaterals. As
688 illustrated in Fig. 7*D*, the four groups (wt, n = 13; pGFAP-BDNF, n = 15; 5xFAD, n =
689 11; 5xF:pGB, n = 13) presented similar increases [$F_{(57,912)} = 1.460$; $p < 0.017$; two-way
690 repeated measures ANOVA] in the slope of fEPSP evoked in CA1 by stimuli presented
691 to the ipsilateral Schaffer collaterals. No significant differences $F_{(3,912)} = 0.718$; $p =$
692 0.546] between the four collected curves were observed. These two relationships were
693 best fitted by sigmoid curves ($r \geq 0.99$; $P < 0.0001$; not illustrated), suggesting a normal
694 basal function of the CA3-CA1 synapses in the four mouse genotypes.
695 Changes in synaptic strength evoked by a pair of pulses are a form of
696 presynaptic short-term plasticity, mostly related to variations in neurotransmitter release

(Zucker and Regehr, 2002). In this regard, paired-pulse stimulation is commonly used as an indirect measurement of changes in the probability of neurotransmitter release at presynaptic terminals of hippocampal synapses (Zucker and Regehr, 2002). In addition, it has been shown that these synaptic properties can be studied in alert behaving mice (Madronal et al., 2009). The paired-pulse facilitation evoked in the four groups (wt, n = 15; pGFAP-BDNF, n = 19; 5xFAD, n = 13; 5xF:pGB, n = 14) was analyzed presenting a fix stimulus intensity (30-40% of asymptotic values) with increasing inter-pulse intervals (see Methods). As illustrated in Fig. 7*E*, the four groups of mice presented a paired pulse facilitation at short (10, 20, and 40 ms) inter-pulse intervals [$F_{(5,240)}$ = 21.290; $p < 0.001$]. However, no significant differences were observed between groups [$F_{(15,240)} = 0.464$; $p = 0.956$].

Finally, we carried out an LTP study in the four groups of behaving mice. It is generally accepted that CA3-CA1 synapses is involved in the acquisition of different types of associative (classical eye blink conditioning) and non-associative (object recognition, spatial orientation) learning tasks and it is usually selected for evoking LTP in behaving mice (Gruart et al., 2006). For baseline values, animals were stimulated at the implanted Schaffer collaterals 3 times/min for 15 min (Fig. 7*F*). Then, animals (wt, n = 16; pGFAP-BDNF, n = 19; 5xFAD, n = 13; 5xF:pGB, n = 14) were presented with the selected HFS protocol (see dashed line in Fig. 7*f*). Following HFS, the same single stimulus used to generate baseline records was presented at the initial rate (3/min) for another 60 min. Recording sessions were repeated for three additional days (30 min each; Fig. 7*F*). The four groups of mice presented a significant increase in fEPSP slopes following the HFS session [$F_{(114,1976)} = 1.863$; $p < 0.001$]. Nevertheless, a point to point comparison between fEPSPs evoked in the four groups of mice after the HFS protocol

721 indicated that 5xF:pGB animals presented larger LTP values for the first recording
722 session ($p \leq 0.045$) than the three other groups.

723 The inset in Fig. 7*F* illustrates the evolution of paired-pulse facilitation in the
724 four groups of mice. In accordance with previous descriptions (Madronal et al., 2009),
725 and as observed here for wt, pGFAP-BDNF, and 5xF:pGB mice, paired-pulse
726 facilitation decreased immediately after HFS and was recovered in the following days.
727 Interestingly, the 5xFAD group did not show any sign of recovery of paired-pulse
728 facilitation for the four recording days after the HFS session, indicating an increase in
729 the response of to the 1st pulse in this stressful situation.

730 In conclusion, the four groups of mice presented similar basal synaptic
731 properties and short-term plasticity. Interestingly, although the four groups of mice
732 presented a significant LTP with respect to baseline values, LTP was significantly larger
733 in the 5xF:pGB group than in the other three groups during the first recording session
734 following the HFS protocol. The 5xFAD group presented LTP values like those reached
735 by wt and pGFAP-BDNF group; this result could be ascribed to an increase in
736 neurotransmitter release evoked by a first pulse, since their paired-pulse facilitation was
737 decreased and remained in this situation across the four recording sessions after HFS.
738
739

740 ## Discussion

741 In the present study we tested an approach to deliver BDNF in a conditional targeted
742 fashion in an AD mouse model. We used a transgenic mouse model recently generated
743 and characterized by our team (Giralt et al., 2010;Giralt et al., 2011) to overexpress
744 BDNF under the GFAP promoter. Here we show how this method restores the
745 production and delivery of the neurotrophin in the diseased neural tissue when the

746 pathology starts because of the accompanying astrogliosis. We first observed that
747 endogenous BDNF from astrocytes regulates neurite formation and spine density in
748 neurons *in vitro*. We then used a *pGFAP*:BDNF transgene to rescue the BDNF loss in
749 5xFAD mice and observed a significant improvement of learning and memory deficits
750 in the hybrid transgenic mice. These improvements were associated with a restoration of
751 dendritic spines density and morphology and a recovery of clusters of pre- and post-
752 synaptic markers, synaptophysin and PSD-95. We also observed a stronger LTP in CA1
753 *in vivo* in behaving 5xF:pGB mice which could be related with the other changes.

754 We first demonstrated that BDNF produced by astrocytes can play a relevant
755 role in dendrite maturation. Although the present results do not demonstrate a clear *in*
756 *vivo* proof that BDNF is produced and released in physiological conditions, they are in
757 line with the idea that astrocytes may play a role in synapse formation and plasticity
758 (Ronzano, 2017) and could play such role by regulating the BDNF availability to
759 neurons (Vignoli et al., 2016). They also reinforce the idea of astrocytes as potent
760 regulators of neurotrophins availability to neurons. After showing that astrocytes are a
761 potential source of BDNF with morphological effects on neurons delivery we generated
762 the double mutant mice 5xF:pGB. We demonstrated that BDNF levels and the
763 activation of TrkB and its downstream pathways (PLCγ and ERK1/2) were fully
764 recovered in these double mutant 5xF:pGB mice, which are the most important
765 regulating synaptic plasticity pathways upon TrkB activation (Yoshii and Constantine-
766 Paton, 2010). Indeed, PLCγ downstream signaling is essential for hippocampal
767 associative learning and CA3-CA1 LTP (Gruart et al., 2007;Minichiello et al., 2002).

768 By comparing these double mutant mice with 5xFAD mice, we observed that the
769 cognitive alterations related to hippocampal dysfunction were rescued. Regarding the
770 neuropathology, genetically recovered BDNF levels did not change astrogliosis in

771 5xFAD mice. Normalization of BDNF levels increased the number of plaques but
772 reduced their size. These findings contrast with the belief that reduced plaque number
773 associates with an amelioration of the 5xFAD mice phenotype (Murphy and LeVine,
774 III, 2010). However, the role of plaques is complex and previous reports have correlated
775 a hyper-aggregation of Aβ with an improvement in AD transgenic mice phenotype due
776 to a lower presence of soluble Aβ, which is the most toxic form of the molecule
777 (Castellani et al., 2009;Cohen et al., 2009;Lublin and Gandy, 2010). We also checked
778 for neurogenesis in the dentate gyrus, which has been described to be altered (Moon et
779 al., 2014), as a possible neural correlate of the observed improvements. However, the
780 number of Ki67-positive cells in the dentate gyrus were equally reduced in 5xFAD and
781 5xF:pGB compared to wild type mice. These results revealed that behavioral
782 improvements in 5xF:pGB mice did not result from plaque number reduction or
783 neurogenesis improvement. We therefore hypothesized that the rescued phenotype in
784 5xF:pGB mice could be rather due to changes in structural and functional synaptic
785 properties. In 5xFAD mice, as well as in AD patients, there is a prominent dendritic
786 spine pathology and loss of synaptic markers such as synaptophysin and PSD-95
787 (Crowe and Ellis-Davies, 2014;Dorostkar et al., 2015;Hongpaisan et al., 2011;Yang et
788 al., 2015;Yuki et al., 2014). We found several synaptic changes associated with the
789 cognitive improvements in 5xF:pGB mice. We hypothesize that BDNF delivered from
790 transgenic astrocytes may have induced these changes by re-activating the neuronal
791 TrkB-PLCγ/ERK1/2 pathway. The PLCγ pathway is important for correct PSD-95
792 location whereas BDNF-TrkB-ERK is important for PSD-95 expression (Parsons et al.,
793 2014;Robinet and Pellerin, 2011;Yoshii and Constantine-Paton, 2014). BDNF signaling
794 can also regulate synaptophysin levels (Tartaglia et al., 2001;Zhang et al., 2017) and its
795 function/location (Bamji et al., 2006). BDNF could also be directly responsible for the

796 rescue of dendritic spine density and morphology as described elsewhere (Kellner et al.,
797 2014). However, although here we show that BDNF from astrocytes activates TrkB in
798 neurons we cannot rule out a collateral effect of BDNF on neighboring astrocytes or
799 even microglia as previously described in the literature (Sasi et al., 2017; Mizoguchi et
800 al., 2011) producing a more widespread effect than the one specifically evaluated in the
801 present work. Overall, our results strongly indicate that 5xF:pGB mice improvements
802 could be due to a local and self-regulated delivery of BDNF in the diseased tissue,
803 likely rescuing the ERK1/2 and PLCγ pathways in neurons, which in turn improved
804 dendritic spine pathology.

805 A significant body of evidence indicates that enhancement of the BDNF delivery
806 or function via activation of its high-affinity receptor TrkB could be a promising
807 therapeutic approach in AD (Allen and Dawbarn, 2006;Devi and Ohno, 2012;Devi and
808 Ohno, 2015;Kaminari et al., 2017;Zhang et al., 2014). Based on our results, we propose
809 that the use of engineered astrocytes could be an interesting means to achieve this
810 objective. Astrocytes are currently considered as very promising potential targets for
811 AD treatment, including through genetic manipulation to regulate neurotrophins
812 production (Bronzuoli et al., 2017;Gorshkov et al., 2018). Indeed, astrocytes are
813 uniquely positioned to promote the regeneration of damaged nerve cells or protect
814 existing cells from degeneration and dysfunction in the CNS (Anderson et al.,
815 2016;Blanco-Suarez et al., 2017). At least three main strategies have been proposed,
816 astrocyte transplantation or pharmacological correction of their dysfunction or by its
817 genetic manipulation (Gorshkov et al., 2018). We propose that targeting astrocytes to
818 produce and deliver BDNF could be a potential therapeutic tool for the treatment of AD.
819 Several previous and present evidences support this idea. First, astrocytes have been
820 recently shown to be crucial for hippocampal-related cognitive function and synaptic

821 plasticity (Adamsky et al., 2018). Second, facilitating BDNF expression from astrocytes
822 has previously been shown to be useful in another neurodegenerative disease,
823 Huntington's disease (Corbett et al., 2013;Giralt et al., 2011;Reick et al., 2016).
824 Furthermore, astrocytes *per se* not only produce but also buffer BDNF in case of
825 necessity (Stary et al., 2015) or recycle it for LTP maintenance and memory retention
826 (Vignoli et al., 2016) thus making them perfect candidates to deliver the neurotrophin in
827 a controlled fashion. Additionally, in the field of cell therapy, astrocytes would be good
828 therapeutic tools because they survive for a long time when grafted (Giralt et al., 2010)
829 and they are specifically reactive where Aβ is accumulated and where neuritic
830 dystrophy is localized (Song et al., 2015). Furthermore, astrocytes are easily
831 manipulated, do not proliferate aberrantly as for example engineered cell lines
832 (Hoffman et al., 1993) and they do not suffer of teratogenic potential, in contrast to stem
833 cells (Martinez-Serrano and Bjorklund, 1996;Pineda et al., 2007;Rubio et al., 1999).
834 Neural cells may be another candidate source for the overexpression of BDNF.
835 However, as an excessive amount of this neurotrophin is deleterious (Kells et al., 2008),
836 its release must be controlled (Martinez-Serrano and Bjorklund, 1996;Rubio et al.,
837 1999). Transgenic astrocytes would overcome all these drawbacks. A promising
838 therapeutic strategy could be the use of astrocytes from induced pluripotent stem cells
839 (Gorshkov et al., 2018). Once astrocytes have been obtained and characterized and
840 genetically modified to express BDNF under the GFAP promoter, they could be
841 transplanted to promote the survival and appropriate functioning of existing neurons
842 such as synaptic plasticity processes.

843 Although 5xFAD mice presented noticeable losses in the expression of PSD-95
844 and synaptophysin, they did not present any significant alteration in input/output curves,
845 paired-pulse facilitation, or in LTP evoked *in vivo*. In this regard, it has been already

reported that LTP can be preserved longer than other behavioral functions in aging mice (Lopez-Ramos et al., 2012) and that motor exercise can help to recover some behavioral and associative learning abilities, but not synaptic changes and LTP in 3xTg-AD mice (Garcia-Mesa et al., 2011). In addition, age seems to be a critical factor—for example, in 3-month old mice it is almost impossible to distinguish differences in learning abilities and LTP strength and duration between wt vs. APP, PS1, and APP-PS1 mice (Gruart et al., 2008). For the present experiments, we can assume that baseline measures of transmission (input/output curves and paired pulse facilitation) and LTP were sustained in 8-month old 5xFAD mice by an increase in neurotransmitter release (Fig. 7*F*), as reported by some of us in TgNTRK3 transgenic mice (Sahun et al., 2007). Indeed, the latter study is an excellent example of dissociation between CA3-CA1 synaptic plasticity and associative learning capabilities in genetically manipulated mice.

The present results have some limitations. First, although the 5xFAD mouse model has been shown to recapitulate several hallmarks of AD pathology they do not show tauopathy or formation of intra-neuronal neurofibrillary tangles. From a therapeutic point of view the interpretation of our results should be taken with caution and studies evaluating our approach in models of tauopathy are needed. Second, we observed recovered BDNF levels in 5xF:pGB mice with respect to 5xFAD mice at 8 months of age, but we cannot rule out the possibility that earlier beneficial effects could have taken place in our double mutant mice. It is known that astrocytes synthesize GFAP from the first days of age (Guo et al., 2013). Thereby, putative early increases on BDNF levels in 5xF:pGB mice could also counteract the deleterious effects of the five transgenic mutations at very early stages.

In conclusion, our study supports the idea that the use of engineered astrocytes to deliver BDNF under the control of the GFAP promoter in AD has a strong potential.

It may correspond to the increase of a physiological function and the delivery is conditionally and locally administrated creating then a customized neurotrophin-based treatment.

Authors' contributions

BdP run most of the *in vitro* and *in vivo* experiments; CDC performed the electronic microscopy and analysis; EM performed the Golgi staining and counted and analyzed the dendritic spines; ATF performed behavioral and histological experiments and posterior analysis; ASB performed western blot and immunofluorescence experiments, LLM performed some astrocyte cultures and run the Q-PCR experiments, AL helped BdP in all the experiments, MAGC performed the electrophysiological experiments; AGr and JMDG designed and wrote the electrophysiological experiments and contributed to writing the manuscript. SG and JA provided the pGFAP-BDNF mice and contributed to writing the manuscript along with JAG. AGi designed the experiments and wrote the manuscript.

References

Acosta C, Anderson HD, Anderson CM (2017) Astrocyte dysfunction in Alzheimer disease. J Neurosci Res 95:2430-2447.

Adamsky A, Kol A, Kreisel T, Doron A, Ozeri-Engelhard N, Melcer T, Refaeli R, Horn H, Regev L, Groysman M, London M, Goshen I (2018) Astrocytic Activation Generates De Novo Neuronal Potentiation and Memory Enhancement. Cell 174:59-71.

Allen SJ, Dawbarn D (2006) Clinical relevance of the neurotrophins and their receptors. Clin Sci (Lond) 110:175-191.

899 Alzheimer's Association (2012) 2012 Alzheimer's disease facts and figures. Alzheimers
900 Dement 8:131-168.

901 Anderson MA, Burda JE, Ren Y, Ao Y, O'Shea TM, Kawaguchi R, Coppola G, Khakh
902 BS, Deming TJ, Sofroniew MV (2016) Astrocyte scar formation aids central nervous
903 system axon regeneration. Nature 532:195-200.

904 Bamji SX, Rico B, Kimes N, Reichardt LF (2006) BDNF mobilizes synaptic vesicles
905 and enhances synapse formation by disrupting cadherin-beta-catenin interactions. J Cell
906 Biol 174:289-299.

907 Blanco-Suarez E, Caldwell AL, Allen NJ (2017) Role of astrocyte-synapse interactions
908 in CNS disorders. J Physiol 595:1903-1916.

909 Bronzuoli MR, Facchinetti R, Steardo L, Scuderi C (2017) Astrocyte: An Innovative
910 Approach for Alzheimer's Disease Therapy. Curr Pharm Des 23:4979-4989.

911 Carpenter MK, Winkler C, Fricker R, Emerich DF, Wong SC, Greco C, Chen EY, Chu
912 Y, Kordower JH, Messing A, Bjorklund A, Hammang JP (1997) Generation and
913 transplantation of EGF-responsive neural stem cells derived from GFAP-hNGF
914 transgenic mice. Exp Neurol 148:187-204.

915 Castellani RJ, Lee HG, Siedlak SL, Nunomura A, Hayashi T, Nakamura M, Zhu X,
916 Perry G, Smith MA (2009) Reexamining Alzheimer's disease: evidence for a protective
917 role for amyloid-beta protein precursor and amyloid-beta. J Alzheimers Dis 18:447-452.

918 Cohen E, Paulsson JF, Blinder P, Burstyn-Cohen T, Du D, Estepa G, Adame A, Pham
919 HM, Holzenberger M, Kelly JW, Masliah E, Dillin A (2009) Reduced IGF-1 signaling
920 delays age-associated proteotoxicity in mice. Cell 139:1157-1169.

921 Corbett GT, Roy A, Pahan K (2013) Sodium phenylbutyrate enhances astrocytic
922 neurotrophin synthesis via protein kinase C (PKC)-mediated activation of cAMP-
923 response element-binding protein (CREB): implications for Alzheimer disease therapy.
924 J Biol Chem 288:8299-8312.

925 Crowe SE, Ellis-Davies GC (2014) Spine pruning in 5xFAD mice starts on basal
926 dendrites of layer 5 pyramidal neurons. Brain Struct Funct 219:571-580.

927 Devi L, Ohno M (2012) 7,8-dihydroxyflavone, a small-molecule TrkB agonist, reverses
928 memory deficits and BACE1 elevation in a mouse model of Alzheimer's disease.
929 Neuropsychopharmacology 37:434-444.

930 Devi L, Ohno M (2015) TrkB reduction exacerbates Alzheimer's disease-like signaling
931 aberrations and memory deficits without affecting beta-amyloidosis in 5XFAD mice.
932 Transl Psychiatry 5:e562.

933 Dorostkar MM, Zou C, Blazquez-Llorca L, Herms J (2015) Analyzing dendritic spine
934 pathology in Alzheimer's disease: problems and opportunities. Acta Neuropathol 130:1-
935 19.

936 Ernfors P, Lee KF, Jaenisch R (1994) Mice lacking brain-derived neurotrophic factor
937 develop with sensory deficits. Nature 368:147-150.

938 Filali M, Lalonde R, Rivest S (2009) Cognitive and non-cognitive behaviors in an
939 APPswe/PS1 bigenic model of Alzheimer's disease. Genes Brain Behav 8:143-148.

940 Fulmer CG, VonDran MW, Stillman AA, Huang Y, Hempstead BL, Dreyfus CF (2014)
941 Astrocyte-derived BDNF supports myelin protein synthesis after cuprizone-induced
942 demyelination. J Neurosci 34:8186-8196.

943 Garcia-Mesa Y, Lopez-Ramos JC, Gimenez-Llort L, Revilla S, Guerra R, Gruart A,
944 Laferla FM, Cristofol R, Delgado-Garcia JM, Sanfeliu C (2011) Physical exercise
945 protects against Alzheimer's disease in 3xTg-AD mice. J Alzheimers Dis 24:421-454.

946 Giralt A, Brito V, Chevy Q, Simonnet C, Otsu Y, Cifuentes-Diaz C, de PB, Coura R,
947 Alberch J, Gines S, Poncer JC, Girault JA (2017) Pyk2 modulates hippocampal
948 excitatory synapses and contributes to cognitive deficits in a Huntington's disease
949 model. Nat Commun 8:15592.

950 Giralt A, Carreton O, Lao-Peregrin C, Martin ED, Alberch J (2011) Conditional BDNF
951 release under pathological conditions improves Huntington's disease pathology by
952 delaying neuronal dysfunction. Mol Neurodegener 6:71.

953 Giralt A, de PB, Cifuentes-Diaz C, Lopez-Molina L, Farah AT, Tible M, Deramecourt
954 V, Arold ST, Gines S, Hugon J, Girault JA (2018) PTK2B/Pyk2 overexpression
955 improves a mouse model of Alzheimer's disease. Exp Neurol 307:62-73.

956 Giralt A, Friedman HC, Caneda-Ferron B, Urban N, Moreno E, Rubio N, Blanco J,
957 Peterson A, Canals JM, Alberch J (2010) BDNF regulation under GFAP promoter
958 provides engineered astrocytes as a new approach for long-term protection in
959 Huntington's disease. Gene Ther 17:1294-1308.

960 Giralt A, Rodrigo T, Martin ED, Gonzalez JR, Mila M, Cena V, Dierssen M, Canals
961 JM, Alberch J (2009) Brain-derived neurotrophic factor modulates the severity of
962 cognitive alterations induced by mutant huntingtin: involvement of
963 phospholipaseCgamma activity and glutamate receptor expression. Neuroscience
964 158:1234-1250.

965 Gorshkov K, Aguisanda F, Thorne N, Zheng W (2018) Astrocytes as targets for drug
966 discovery. Drug Discov Today 23:673-680.

967 Grinan-Ferre C, Sarroca S, Ivanova A, Puigoriol-Illamola D, Aguado F, Camins A,
968 Sanfeliu C, Pallas M (2016) Epigenetic mechanisms underlying cognitive impairment
969 and Alzheimer disease hallmarks in 5XFAD mice. Aging (Albany NY) 8:664-684.

970 Gruart A, Lopez-Ramos JC, Munoz MD, Delgado-Garcia JM (2008) Aged wild-type
971 and APP, PS1, and APP + PS1 mice present similar deficits in associative learning and
972 synaptic plasticity independent of amyloid load. Neurobiol Dis 30:439-450.

973 Gruart A, Munoz MD, Delgado-Garcia JM (2006) Involvement of the CA3-CA1
974 synapse in the acquisition of associative learning in behaving mice. J Neurosci 26:1077-
975 1087.

976 Gruart A, Sciarretta C, Valenzuela-Harrington M, Delgado-Garcia JM, Minichiello L
977 (2007) Mutation at the TrkB PLC{gamma}-docking site affects hippocampal LTP and
978 associative learning in conscious mice. Learn Mem 14:54-62.

979 Guo Z, Wang X, Xiao J, Wang Y, Lu H, Teng J, Wang W (2013) Early postnatal
980 GFAP-expressing cells produce multilineage progeny in cerebrum and astrocytes in
981 cerebellum of adult mice. Brain Res 1532:14-20.

982 Gupta VK, You Y, Gupta VB, Klistorner A, Graham SL (2013) TrkB receptor
983 signalling: implications in neurodegenerative, psychiatric and proliferative disorders. Int
984 J Mol Sci 14:10122-10142.

985 Gureviciene I, Ikonen S, Gurevicius K, Sarkaki A, van GT, Pussinen R, Ylinen A,
986 Tanila H (2004) Normal induction but accelerated decay of LTP in APP + PS1
987 transgenic mice. Neurobiol Dis 15:188-195.

988 Hoffman D, Breakefield XO, Short MP, Aebischer P (1993) Transplantation of a
989 polymer-encapsulated cell line genetically engineered to release NGF. Exp Neurol
990 122:100-106.

991 Hong Y, Zhao T, Li XJ, Li S (2016) Mutant Huntingtin Impairs BDNF Release from
992 Astrocytes by Disrupting Conversion of Rab3a-GTP into Rab3a-GDP. J Neurosci
993 36:8790-8801.

994 Hongpaisan J, Sun MK, Alkon DL (2011) PKC epsilon activation prevents synaptic
995 loss, Abeta elevation, and cognitive deficits in Alzheimer's disease transgenic mice. J
996 Neurosci 31:630-643.

997 Kaminari A, Giannakas N, Tzinia A, Tsilibary EC (2017) Overexpression of matrix
998 metalloproteinase-9 (MMP-9) rescues insulin-mediated impairment in the 5XFAD
999 model of Alzheimer's disease. Sci Rep 7:683.

1000 Kellner Y, Godecke N, Dierkes T, Thieme N, Zagrebelsky M, Korte M (2014) The
1001 BDNF effects on dendritic spines of mature hippocampal neurons depend on neuronal
1002 activity. Front Synaptic Neurosci 6:5.

1003 Kells AP, Henry RA, Connor B (2008) AAV-BDNF mediated attenuation of quinolinic
1004 acid-induced neuropathology and motor function impairment. Gene Ther 15:966-977.

1005 Lalonde R (2002) The neurobiological basis of spontaneous alternation. Neurosci
1006 Biobehav Rev 26:91-104.

1007 Lindvall O, Kokaia Z, Martinez-Serrano A (2004) Stem cell therapy for human
1008 neurodegenerative disorders-how to make it work. Nat Med 10 Suppl:S42-S50.

1009 Lopez-Ramos JC, Jurado-Parras MT, Sanfeliu C, Acuna-Castroviejo D, Delgado-Garcia
1010 JM (2012) Learning capabilities and CA1-prefrontal synaptic plasticity in a mice model
1011 of accelerated senescence. Neurobiol Aging 33:627-26.

1012 Lublin AL, Gandy S (2010) Amyloid-beta oligomers: possible roles as key neurotoxins
1013 in Alzheimer's Disease. Mt Sinai J Med 77:43-49.

1014 Lynch G, Rex CS, Chen LY, Gall CM (2008) The substrates of memory: defects,
1015 treatments, and enhancement. Eur J Pharmacol 585:2-13.

1016 Madronal N, Delgado-Garcia JM, Gruart A (2007) Differential effects of long-term
1017 potentiation evoked at the CA3 CA1 synapse before, during, and after the acquisition of
1018 classical eyeblink conditioning in behaving mice. J Neurosci 27:12139-12146.

1019 Madronal N, Gruart A, Delgado-Garcia JM (2009) Differing presynaptic contributions
1020 to LTP and associative learning in behaving mice. Front Behav Neurosci 3:7.

1021 Martinez-Serrano A, Bjorklund A (1996) Protection of the neostriatum against
1022 excitotoxic damage by neurotrophin-producing, genetically modified neural stem cells.
1023 J Neurosci 16:4604-4616.

1024 Minichiello L, Calella AM, Medina DL, Bonhoeffer T, Klein R, Korte M (2002)
1025 Mechanism of TrkB-mediated hippocampal long-term potentiation. Neuron 36:121-137.

1026 Mizoguchi Y, Monji A, Kato TA, Horikawa H, Seki Y, Kasai M, Kanba S, Yamada S
1027 (2011) Possible role of BDNF-induced microglial intracellular Ca(2+) elevation in the
1028 pathophysiology of neuropsychiatric disorders. Mini Rev Med Chem 11(7):575-81.

1029 Moon M, Cha MY, Mook-Jung I (2014) Impaired hippocampal neurogenesis and its
1030 enhancement with ghrelin in 5XFAD mice. J Alzheimers Dis 41:233-241.

1031 Murphy MP, LeVine H, III (2010) Alzheimer's disease and the amyloid-beta peptide. J
1032 Alzheimers Dis 19:311-323.

1033 Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M,
1034 Disterhoft J, Van EL, Berry R, Vassar R (2006) Intraneuronal beta-amyloid aggregates,
1035 neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's
1036 disease mutations: potential factors in amyloid plaque formation. J Neurosci 26:10129-
1037 10140.

1038 Parsons MP, Kang R, Buren C, Dau A, Southwell AL, Doty CN, Sanders SS, Hayden
1039 MR, Raymond LA (2014) Bidirectional control of postsynaptic density-95 (PSD-95)
1040 clustering by Huntingtin. J Biol Chem 289:3518-3528.

1041 Paxinos G, Franklin KBJ (2013) The mause brain in stereotaxic coordinates. San Diego,
1042 CA: Academic.

1043 Pineda JR, Rubio N, Akerud P, Urban N, Badimon L, Arenas E, Alberch J, Blanco J,
1044 Canals JM (2007) Neuroprotection by GDNF-secreting stem cells in a Huntington's
1045 disease model: optical neuroimage tracking of brain-grafted cells. Gene Ther 14:118-
1046 128.

1047 Reick C, Ellrichmann G, Tsai T, Lee DH, Wiese S, Gold R, Saft C, Linker RA (2016)
1048 Expression of brain-derived neurotrophic factor in astrocytes - Beneficial effects of
1049 glatiramer acetate in the R6/2 and YAC128 mouse models of Huntington's disease. Exp
1050 Neurol 285:12-23.

1051 Robinet C, Pellerin L (2011) Brain-derived neurotrophic factor enhances the
1052 hippocampal expression of key postsynaptic proteins in vivo including the
1053 monocarboxylate transporter MCT2. Neuroscience 192:155-163.

1054 Ronzano R (2017) [Astrocytes and microglia: active players in synaptic plasticity]. Med
1055 Sci (Paris) 33:1071-1078.

1056 Rubio FJ, Kokaia Z, del AA, Garcia-Simon MI, Snyder EY, Lindvall O, Satrustegui J,
1057 Martinez-Serrano A (1999) BDNF gene transfer to the mammalian brain using CNS-
1058 derived neural precursors. Gene Ther 6:1851-1866.

1059 Saha RN, Liu X, Pahan K (2006) Up-regulation of BDNF in astrocytes by TNF-alpha: a
1060 case for the neuroprotective role of cytokine. J Neuroimmune Pharmacol 1:212-222.

1061 Sahun I, Delgado-Garcia JM, Amador-Arjona A, Giralt A, Alberch J, Dierssen M,
1062 Gruart A (2007) Dissociation between CA3-CA1 synaptic plasticity and associative
1063 learning in TgNTRK3 transgenic mice. J Neurosci 27:2253-2260.

1064 Sasi M, Vignoli B, Canossa M, Blum R (2017) Neurobiology of local and intercellular
1065 BDNF signaling. Pflugers Arch. 469(5-6):593-610.

1066 Schneider F, Baldauf K, Wetzel W, Reymann KG (2015) Effects of methylphenidate on
1067 the behavior of male 5xFAD mice. Pharmacol Biochem Behav 128:68-77.

1068 Song MS, Learman CR, Ahn KC, Baker GB, Kippe J, Field EM, Dunbar GL (2015) In
1069 vitro validation of effects of BDNF-expressing mesenchymal stem cells on
1070 neurodegeneration in primary cultured neurons of APP/PS1 mice. Neuroscience 307:37-
1071 50.

1072 Stary CM, Sun X, Giffard RG (2015) Astrocytes Protect against Isoflurane
1073 Neurotoxicity by Buffering pro-brain-derived Neurotrophic Factor. Anesthesiology
1074 123:810-819.

1075 Tartaglia N, Du J, Tyler WJ, Neale E, Pozzo-Miller L, Lu B (2001) Protein synthesis-
1076 dependent and -independent regulation of hippocampal synapses by brain-derived
1077 neurotrophic factor. J Biol Chem 276:37585-37593.

1078 Toda T, Gage FH (2017) Review: adult neurogenesis contributes to hippocampal
1079 plasticity. Cell Tissue Res.

1080 Vignoli B, Battistini G, Melani R, Blum R, Santi S, Berardi N, Canossa M (2016) Peri-
1081 Synaptic Glia Recycles Brain-Derived Neurotrophic Factor for LTP Stabilization and
1082 Memory Retention. Neuron 92:873-887.

1083 von Bohlen Und HO, von Bohlen UH, V (2018) BDNF effects on dendritic spine
1084 morphology and hippocampal function. Cell Tissue Res.

1085 Waterhouse EG, An JJ, Orefice LL, Baydyuk M, Liao GY, Zheng K, Lu B, Xu B
1086 (2012) BDNF promotes differentiation and maturation of adult-born neurons through
1087 GABAergic transmission. J Neurosci 32:14318-14330.

1088 Webster SJ, Bachstetter AD, Nelson PT, Schmitt FA, Van Eldik LJ (2014) Using mice
1089 to model Alzheimer's dementia: an overview of the clinical disease and the preclinical
1090 behavioral changes in 10 mouse models. Front Genet 5:88.

1091 Wirths O, Bayer TA (2012) Intraneuronal Abeta accumulation and neurodegeneration:
1092 lessons from transgenic models. Life Sci 91:1148-1152.

1093 Yang EJ, Ahn S, Ryu J, Choi MS, Choi S, Chong YH, Hyun JW, Chang MJ, Kim HS
1094 (2015) Phloroglucinol Attenuates the Cognitive Deficits of the 5XFAD Mouse Model of
1095 Alzheimer's Disease. PLoS One 10:e0135686.

1096 Yoshii A, Constantine-Paton M (2010) Postsynaptic BDNF-TrkB signaling in synapse
1097 maturation, plasticity, and disease. Dev Neurobiol 70:304-322.

1098 Yoshii A, Constantine-Paton M (2014) Postsynaptic localization of PSD-95 is regulated
1099 by all three pathways downstream of TrkB signaling. Front Synaptic Neurosci 6:6.

1100 Yoshimoto Y, Lin Q, Collier TJ, Frim DM, Breakefield XO, Bohn MC (1995)
1101 Astrocytes retrovirally transduced with BDNF elicit behavioral improvement in a rat
1102 model of Parkinson's disease. Brain Res 691:25-36.

1103 Yuki D, Sugiura Y, Zaima N, Akatsu H, Takei S, Yao I, Maesako M, Kinoshita A,
1104 Yamamoto T, Kon R, Sugiyama K, Setou M (2014) DHA-PC and PSD-95 decrease
1105 after loss of synaptophysin and before neuronal loss in patients with Alzheimer's
1106 disease. Sci Rep 4:7130.

1107 Zhang Y, Qiu B, Wang J, Yao Y, Wang C, Liu J (2017) Effects of BDNF-Transfected
1108 BMSCs on Neural Functional Recovery and Synaptophysin Expression in Rats with
1109 Cerebral Infarction. Mol Neurobiol 54:3813-3824.

1110 Zhang Z, Liu X, Schroeder JP, Chan CB, Song M, Yu SP, Weinshenker D, Ye K (2014)
1111 7,8-dihydroxyflavone prevents synaptic loss and memory deficits in a mouse model of
1112 Alzheimer's disease. Neuropsychopharmacology 39:638-650.

1113 Zucker RS, Regehr WG (2002) Short-term synaptic plasticity. Annu Rev Physiol
1114 64:355-405.
1115
1116
1117

Figure legends

Figure 1. BDNF regulates dendrites and spine number *in vitro*. (***A***) Left panel: BDNF mRNA levels were determined in wild type astrocytes. HEK293 cells were used as negative control (Student's t-test, ($t = 2.496$, $Df = 6$; $p < 0.05$; $n = 3$-5). Right panel: Representative agarose gel. The arrow indicates the molecular weight of the BDNF transcript detected at 114bp (***B***) A scheme showing the experimental design is depicted illustrating the two *in vitro* conditions: $BDNF^{+/+}$ astrocyte monolayer co-cultured with wild type neurons (namely $BDNF^{+/+}$) and $BDNF^{-/-}$ astrocyte monolayer co-cultured with wild type neurons (namely $BDNF^{-/-}$). (***C***) Representative images showing the bright field allowing visualization of the astrocyte monolayer plus some co-cultured neurons on the top, hippocampal neurons stained for MAP2 (in red) and transfected MAP2-positive neurons transfected with a plasmid coding GFP (in green). (***D***) Representative MAP2 images obtained by confocal microscopy from co-cultured astrocytes and neurons (top panel). Scale bar 40 µm. Lower panel: Sholl analysis from MAP2-positive neurons (two-way ANOVA analysis; group effect, $F_{(1, 307)} = 81.7$, $p < 0.001$). (***E***) Spine density was studied using GFP fluorescence in transfected MAP2-positive neurons (left panel). Quantification of spine density (right panel) is shown (Student's t-test, $t = 5.462$, $Df = 70$; $p < 0.001$). Data are means ± SEM. In ***D*** $n = 45$ and 60 MAP2-positive neurons/group from 3 different experiments; in ***E*** $n = 31$ and 41 dendrites/group from 3 different experiments.

Figure 2. Validation of the 5xF:pGB model. Crossing 5xFAD mice with pGFAP-BDNF mice resulted in four genotypes namely wt, pGFAP-BDNF, 5xFAD and the double mutant 5xF:pGB mice. We evaluated these mice at 8 months of age. (***A***) GFAP immunofluorescence microscopy imaging in the dorsal hippocampus of 8-month-old

wt, pGFAP-BDNF, 5xFAD and 5xF:pGB mice. Scale bar, 500 µm. (***B***) Immunoblotting for BDNF, GFAP and tubulin as a loading control in the hippocampus of 8-month-old wt, pGFAP-BDNF, 5xFAD and 5xF:pGB mice. (***C***) Densitometry quantification of BDNF levels as in (***B***). (***D***) Densitometry quantification of GFAP levels as in (***B***). One-way ANOVA, BDNF genotype effect: $F_{(3, 24)} = 4.403$, $p = 0.0103$; GFAP genotype effect: $F_{(3, 25)} = 41.18$, $p < 0.001$. Data were normalized to tubulin for each sample and expressed as a percentage of wild-type. (***E***) Immunoblotting for $pAkt^{ser308}$, $pERK^{T402/Y404}$, $pPLC\gamma^{Y783}$, ERK, Akt and PLCγ and tubulin as a loading control in the hippocampus of 8-month-old wt, pGFAP-BDNF, 5xFAD and 5xF:pGB mice. (***F***) Densitometry quantification of $pAkt^{ser308}$, $pERK^{T402/Y404}$ and $pPLC\gamma^{Y783}$ levels as in (***E***). One-way ANOVA, $pERK^{T402/Y404}$ genotype effect: $F_{(3, 28)} = 29.14$, $p < 0.001$; $pAkt^{ser308}$ genotype effect: $F_{(3, 26)} = 0.5666$, $p < 0.646$; $pPLC\gamma^{Y783}$ genotype effect: $F_{(3, 28)} = 5.251$, $p < 0.0053$. Data were normalized to the corresponding total levels of ERK, Akt and PLCγ for each sample and expressed as a percentage of wild-type. Data are means ± SEM. Tukey's test as a *post hoc* analysis was used in ***C***, ***D*** and ***F***. * $p < 0.05$ and *** $p < 0.001$ as compared to wt mice; $^{\$\$}$ $p < 0.01$ and $^{\$\$\$}$ $p < 0.001$ as compared to 5xFAD mice. In ***B*** and ***E*** molecular weight markers positions are indicated in kDa. In ***C***, ***D*** and ***F*** n = 6-11/group.

Figure 3. Characterization of 5xF:pGB mice. (***A***) wt, pGFAP-BDNF, 5xFAD and mice at 8 months of age were subjected to a comprehensive behavioral characterization. In the Open field, (***A***) locomotor activity and (***B***) time spent in the center of the arena were monitored for 30 min in wt, pGFAP-BDNF, 5xFAD and 5xF:pGB mice. Locomotor activity, two-way ANOVA, genotype effect: $F_{(3, 116)} = 1.2654$, $p = 0.2899$; Time in center, one-way ANOVA: $F_{(3, 80)} = 1.009$, $p = 0.3934$. (***C***) In the plus maze the time

spent in the open arms was monitored for 5 min in the four groups of mice. One-way ANOVA: $F_{(3, 77)} = 6.907$, $p = 0.005$. (***D***) In the novelty-suppressed feeding test the time to reach and eat the pellet in the center of the arena was evaluated in the four genotypes. One-way ANOVA: $F_{(3, 76)} = 1.467$, $p = 0.2303$. (***E***) In the forced swimming test the immobility time was evaluated during the last 4 min of the 6-min trial in all groups. One-way ANOVA: $F_{(3, 80)} = 0.9903$, $p = 0.417$. (***F***) In the novel object location test spatial long-term memory was evaluated 24h after a training trial as the percentage of time exploring the object placed in a new location (NL) versus the time exploring the object placed in an old location (OL). Two-way ANOVA, object in a new location effect: $F_{(3, 150)} = 40.80$, $p < 0.001$. Interaction effect: $F_{(3, 150)} = 7.14$, $p = 0.002$. (***G***) In the Y-maze the spontaneous alternation was measured (as triads) in an 8-min trial in all four genotypes. One-way ANOVA: $F_{(3, 44)} = 7.717$, $p = 0.003$. (***H***) In the passive avoidance paradigm, the latency (sec) to step-through was evaluated in the training trial and in the testing trial 24h after receiving an electric shock (2 sec / 1 mA). One-way ANOVA: $F_{(3, 126)} = 5.384$, $p = 0.0016$. Data are means ± SEM. In ***A-B*** and ***H*** n = 18-25 mice/genotype. In ***G***, n = 12-14 mice/genotype. Tukey's *post hoc* test was used for all behavioral tasks. In ***C***, ***G*** and ***H***: * $p < 0.05$, ** $p < 0.01$ and *** $p < 0.001$ compared to wt; $^{\$}$ $p < 0.05$ and $^{\$\$}$ $p < 0.01$ compared to 5xFAD. In ***F***: * $p < 0.05$ *** and $p < 0.001$ compared to % of time exploring the object in an old location (OL).

Fig. 4 Analysis of gross neuropathology and neurogenesis in wt, pGFAP-BDNF, 5xFAD and 5xF:pGB mice. (***A***) Amyloid plaques images stained with blue toluidine obtained in a bright field microscope in the frontal cortex (upper-left panels) and in the hippocampus (bottom-left panels) of 5xFAD and 5xF:pGB mice at 8 months of age. Scale bar 400 µm. (***B***) The plaque density was determined by manual counting in the

pre-frontal cortex and in the hippocampus of all four genotypes (right panel). Student's unpaired t-test: pre-frontal cortex, $t = 1.923$, $df = 4$, $p = 0.1268$; hippocampus, $t = 7.446$, $df = 4$, $p = 0.0017$. (***C***) Amyloid plaques images obtained with electronic microscopy (left panel). Note that plaques have been colorized for easy visualization for the reader. Black arrows depict the plaque boundary. (***D***) The hippocampal plaques area was determined by using the ImageJ software (right panel). Scale bar 10 µm. Student's unpaired t-test: $t = 4.743$, $df = 8$, $p = 0.0015$. (***E***) Ki67-positive cells obtained by confocal microscopy imaging in the dentate gyrus in 8-month old wt, pGFAP-BDNF, 5xFAD and 5xF:pGB mice (left panel). Scale bar 300 µm. (***F***) Quantification of the number of the Ki67-positive cells per field (right panel). Genotype effect: $F_{(3, 20)} = 5.323$, $p < 0.0073$. Data are means ± SEM. In ***B*** and ***D***: Student's unpaired t-test was used. In ***F***: One-way ANOVA and Tukey's *post hoc* test. In ***B*** and ***D***: * $p < 0.05$ and ** $p < 0.01$ as compared to 5xFAD mice. In ***F***: * $p < 0.01$ as compared to wt mice. In ***B***, n = 4 mice/genotype; in ***D***, n = 4 mice/genotype; in ***F***, n = 6-7 mice/genotype. Ctx: Frontal cortex; Hipp: Hippocampus.

Figure 5. Dendritic spine density and morphology analysis in the pre-frontal cortex and hippocampus of wt, pGFAP-BDNF, 5xFAD and 5xF:pGB mice. (***A***) Images of apical dendrites from pyramidal neurons of the layer V in pre-frontal cortex stained with Golgi staining obtained in a bright field microscope in 8-month-old wt, pGFAP-BDNF, 5xFAD and 5xF:pGB mice. Scale bar 5 µm. (***B***) The dendritic spine density was determined in all four genotypes by using the ImageJ freeware. One-way ANOVA: $F_{(2, 100)} = 23.09$, $p < 0.001$. (***C***) Density of each type of dendritic spine (stubby, thin and mushroom) in apical dendrites of pyramidal neurons of the layer V of the prefrontal cortex in 8-month-old wt, pGFAP-BDNF, 5xFAD and 5xF:pGB mice. Two-way

ANOVA, genotype effect: $F_{(3, 390)} = 21.83$, $p < 0.001$; interaction effect, $F_{(3, 390)} = 6.036$, $p < 0.001$. (***D***) Images of apical dendrites from pyramidal neurons of the hippocampal CA1 stained with Golgi staining obtained in a bright field microscope in 8-month-old wt, pGFAP-BDNF, 5xFAD and 5xF:pGB mice. Scale bar 5 µm. (***E***) The dendritic spine density was determined in all four genotypes by using the ImageJ freeware. One-way ANOVA: $F_{3, 185)} = 4.070$, $p = 0.0079$. (***F***) Density of each type of dendritic spine (stubby, thin and mushroom) in apical dendrites of pyramidal neurons from the hippocampal CA1 in 8-month-old wt, pGFAP-BDNF, 5xFAD and 5xF:pGB mice. Two-way ANOVA, genotype effect: $F_{(3, 552)} = 3.678$, $p = 0.0121$; interaction effect, $F_{(3, 390)} = 2.750$, $p = 0.0122$. Data are means ± SEM. In ***B*** and ***E***: One-way ANOVA with Tukey's test as a *post hoc* was used. In ***C*** and ***F***: Two-way ANOVA and Bonferroni's *post hoc* test. In ***B***-***C*** and ***E***-***F***: * $p < 0.05$, ** $p < 0.01$ and *** $p < 0.001$ as compared to wt mice; $^{\$}$ $p < 0.05$, $^{\$\$}$ $p < 0.01$ and $^{\$\$\$}$ $p < 0.001$ as compared to 5xFAD mice. In ***B*** and ***C***, n = 31-41 dendrites/genotype (from 5 mice/genotype); in ***E*** and ***F***, n = 35-56 dendrites/genotype (from 5 mice/genotype).

Figure 6. Hippocampal excitatory synapses characterization of wt, pGFAP-BDNF, 5xFAD and 5xF:pGB mice. (***A***) Confocal image of PSD-95 immunofluorescence in CA1 *stratum radiatum* of 8-month wt, pGFAP-BDNF, 5xFAD and 5xF:pGB mice. Scale bar 10 µm. (***B***) Quantification of the number of PSD-95-positive puncta per field. One-way ANOVA: $F_{(3, 16)} = 14.90$, $p < 0.001$. (***C***) Synaptophysin immunofluorescence. Scale bar 10 µm. (***D***) Quantification of the number of synaptophysin-positive puncta per field. One-way ANOVA: $F_{(3, 16)} = 7.194$, $p < 0.0028$. (***E***) Confocal image of a double PSD-95 (green) and phosphoTrkB^{Y816} (red) immunofluorescence in CA1 *stratum radiatum* of 8-month wt, pGFAP-BDNF, 5xFAD and 5xF:pGB mice. Scale bar 10 µm.

(***F***) Quantification of the number of PSD-95/phosphoTrkB^{Y816}-positive puncta per field. One-way ANOVA: $F_{(3, 26)} = 5.303$, $p < 0.01$. (***G***) Electronic microscopy imaging of excitatory synapses in the stratum radiatum of the CA1 in 8-month-old wt, pGFAP-BDNF, 5xFAD and 5xF:pGB mice. Asterisks indicate the pre-synaptic component and black arrows indicate the post-synaptic component. Scale bar 0.3 µm. (***H***) Quantification of the post-synaptic density area. One-way ANOVA: $F_{(3, 253)} = 17.16$, $p < 0.001$. (***I***) Quantification of the number of pre-synaptic vesicles per synapse. One-way ANOVA: $F_{(3, 201)} = 9.18$, $p < 0.001$. One-way ANOVA with Tukey's test as a *post hoc* was used. Data are means + SEM. . In ***B, D, F, H*** and ***I***: * $p < 0.05$ and *** $p < 0.001$ as compared to wt mice; $^{\$\$}$ $p < 0.01$ and $^{\$\$\$}$ $p < 0.001$ as compared to 5xFAD mice. In ***B***, ***D*** and ***F***, 2 pictures per slice and 3 slices per mouse were taken. In ***B*** and ***D*** n = 5/genotype. In ***F*** n = 7-9/genotype. In ***H*** and ***I***, 51 ± 3 excitatory synapses from 3 different mice / genotype were evaluated.

Figure 7. *In vivo* hippocampal synaptic plasticity in wt, pGFAP-BDNF, 5xFAD and 5xF:pGB mice. (***A***) Animals were chronically implanted with bipolar stimulating electrodes in CA3 Schaffer (Sch.) collaterals and with a recording electrode in the ipsilateral CA1 area. Two extra wires were attached to the bone as ground. DG, dentate gyrus. At the right is illustrated a representative example of fEPSP (averaged 5 times) evoked at the CA3-CA1 synapse in a wt animal. (***B***) A diagram illustrating the location of stimulating and recording electrodes in the intrinsic hippocampal circuit. (***C***) Representative micrographs illustrating the final location of stimulating and recording electrodes. D, L, M, V, dorsal, lateral, medial, and ventral. Calibration bar: 0.2 mm. (***D***) Input/output curves of fEPSPs evoked at the CA3-CA1 synapse by single pulses of increasing intensities (0.02-0.4 in mA) in wt (n = 13), pGFAP-BDNF (n = 15), 5xFAD

(n = 11), and 5xF:pGB (n = 13) mice. Data is represented as mean ± SEM. No significant differences [$F_{(3,912)} = 0.718$; $p = 0.546$] were observed between groups. (***E***) No significant [$F_{(15,240)} = 0.464$; $p = 0.956$] differences in paired-pulse facilitation between the four experimental groups were observed (wt = 15; pGFAP-BDNF = 19; 5xFAD = 13; 5xF:pGB = 14). Data shown are mean ± SEM slopes of the 2nd fEPSP expressed as the percentage of the 1st for six (10, 20, 40, 100, 200, 500) inter-pulse intervals. (***F***) Graphs illustrating the time course of LTP evoked in the CA3-CA1 synapse following an HFS session presented to mice included in the four experimental groups (wt, n = 16; pGFAP-BDNF, n = 19; 5xFAD, n = 13; 5xF:pGB, n = 14). The HFS was presented after 15 min of baseline recordings, at the time marked by the dashed line. LTP evolution was followed for three days. At the top are illustrated representative examples of fEPSPs collected at the times indicated in the bottom graphs from a representative animal of each group. fEPSP slopes are given as a percentage of fEPSP values collected during baseline recordings (100%). Although the four groups presented significant [$F_{(114,1976)} = 1.863$; $p < 0.001$] increases (ANOVA, two-tailed) in fEPSP slopes following HFS when compared with baseline recordings, the 5xF:pGB group did present a larger LTP than that presented by the other three groups (*, 5xF:pGB vs. wt; $^{+}$, 5xF:pGB vs. pGFAP-BDNF; and $^{\&}$, 5xF:pGB vs. 5xFAD; $p \leq 0.045$). The evolution of paired-pulse facilitation (determined at 40 ms of inter-pulse interval) for fEPSPs recorded during baseline and following the HFS session is illustrated at the top-left inset for the four experimental groups. For clarity, data corresponding to the 5xFAD group is indicated by the dots-and-dashes line.